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5I Preface
The EMCDDA’s 2014 European Drug Report (EDR) presents a new analysis of the drug 
situation, accompanied by an overview of developments in interventions and policies. 
Rooted in a comprehensive review of both European and national data, the EDR package 
offers an interlinked range of products, with the Trends and developments report at its 
centre. By taking a multi-dimensional approach, an in-depth analysis of key topics is 
presented alongside a more top-level overview of major issues and long-term trends. This 
perspective is of value, as it allows differing national experiences to be understood within 
the broader context offered by European-level data. Whatever your interests in the 
European drug situation, we are confident that the new EDR package will allow you easy 
access to high-quality information and analysis in a form appropriate to your specific needs.
A set of interlinked elements allowing full access to the available data  
and analysis on the drug problem in Europe
Trends and  
developments
providing a top-level 
analysis of key  
developments (print  
and online)
Data and statistics
containing full data  
arrays, graphics  
and methodological  
information (online)
Country overviews
national data  
and analysis at your  
fingertips (online)
Perspectives  
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interactive windows  
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EUROPEAN DRUG REPORT PACKAGE 2014
200 000
150 000
100 000
50 000
0
2006 2007 2008 2009 2010 2011
E
U
R
O
P
E
A
N
 D
R
U
G
 R
E
P
O
R
T
 2
0
1
4
    Tren
d
s an
d
 d
evelop
m
en
ts
2014
EN
Trends and developments
IS
S
N
 1
9
7
7
-9
8
6
0
European
Drug
Report
Progress has been made in developing a balanced policy response to drug problems in 
Europe, and this is an important message coming from this year’s analysis. In some key 
public health areas, the overall trends are now positive, and in relative global terms, the 
European model appears to be a successful one. The drug phenomenon is dynamic and 
continues to evolve, leaving us no room for complacency, as new threats emerge to 
accompany residual and long-established problems. The drugs that we see today are, in 
many ways, different from those we knew in the past. We see this in the established drugs, 
a notable example being cannabis, where new production techniques are impacting on the 
potency of both resin and herbal products. We see this also in synthetic drug production, 
with a plethora of new substances appearing. It must be a serious concern that, recently, 
we have witnessed the emergence of both new synthetic opioids and hallucinogenic 
substances that are so highly pharmacologically active that even tiny quantities can be 
used to produce multiple doses. We are only beginning to grasp the future implications of 
these developments for both public health and drug control, but they do appear to have 
the potential to transform the nature of the problems we face.
European Drug Report 2014: Trends and developments
6
Not only are important changes taking place in the European drug market, they are 
occurring at an ever greater pace and within the context of an increasingly interconnected 
world. The EMCDDA recognises the global and dynamic nature of our subject matter, and 
the challenges this poses. Moreover, these developments place our current monitoring 
systems under increasing strain, and it is critical to ensure that our surveillance tools 
remain fit for purpose. Nearly two decades ago, Europe was the first to establish an 
early-warning system to identify potential new threats in this area. Today, the system has 
proved its worth, but nevertheless our overall forensic capacity to identify and report on the 
public health consequences of both established and new substances remains insufficient. 
We can only note here the importance of ensuring that sufficient resources are made 
available for maintaining and strengthening work in this area, and highlight the added 
value that this provides to the European community as a whole.
Finally, we take pride in the comprehensive analysis provided by the EDR package and that 
our work continues to provide a scientific bedrock for informing European policies and 
responses. We strongly believe, now more than ever, that this is important, and we will 
continue to strive to provide a timely, objective and balanced analysis of today’s complex 
and changing drug problem. 
João Goulão 
Chairman of the EMCDDA Management Board
Wolfgang Götz 
Director, EMCDDA
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This report is based on information provided to the EMCDDA in the form of a national 
report by the EU Member States, the candidate country Turkey, and Norway. 
Statistical data reported here are for 2012, or the most recent year available. European 
totals and trends are based on those countries providing sufficient and relevant data for 
the period specified. The data analysis prioritises levels, trends and geographical 
distribution. The necessary technical caveats and qualifications of the data may be found 
in the English language online version of this report and in the online European Drug 
Report: Data and statistics, where information on methodology, reporting countries and 
years is available. In addition, the online version provides links to further resources. 
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Analysis Core Group Europe (SCORE) and the Swedish Council for Information on 
Alcohol and Other Drugs (CAN);
   the Translation Centre for the Bodies of the European Union, Missing Element Designers 
and Composiciones Rali.
Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The 
network is comprised of national focal points in the EU Member States, the 
candidate country Turkey, Norway and at the European Commission. Under the 
responsibility of their governments, the focal points are the national authorities 
providing drug information to the EMCDDA. The contact details of the national focal 
points may be found on the EMCDDA website.
 This report provides a top-level  
 overview of the long-term trends  
 and developments in Europe,  
 while also focusing in on emerging  
 drug-related problems 
Summary
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Summary
Charting the public health 
impact of drugs in a changing 
European market
The main findings in the EMCDDA’s new 
analysis of the European drug problem 
remain consistent with our 2013 report: 
the overall situation is generally stable, 
with positive signs in some areas, but 
new challenges continue to emerge. 
The old dichotomy between a relatively 
small number of highly problematic 
drug users, often injecting, and a larger 
number of recreational and 
experimental users, is breaking down 
and being replaced by a more 
graduated and complex situation. 
In Europe’s drug problem today, heroin 
plays a lesser part than it did in the 
past, and stimulants, synthetic drugs, 
cannabis and medicinal products are 
all becoming more important.
Looking at the ‘big picture’, progress has been made on a 
number of the major public health policy objectives of the 
past. A European-level perspective can, however, obscure 
important national differences. This is illustrated by data 
on overdose deaths and drug-related HIV infections; two of 
the most serious consequences of drug use. Here, an 
overall positive EU trend sits in sharp contrast to worrying 
developments in some countries. Recognising this 
complexity, this report provides a top-level overview of the 
long-term trends and developments in Europe, while also 
focusing in on emerging drug-related problems.
I  Heroin in decline, but replacement substances cause concern
While noting that globally, heroin production estimates 
remain high, and seizures in Turkey have partially 
rebounded, overall, heroin indicators are generally stable 
or trending downwards. This includes data showing a 
continuing decline in heroin-related treatment entry, 
alongside overall, long-term downward trends in drug 
overdose deaths and drug-acquired HIV infection — both 
historically linked to injecting heroin use. These positive 
developments are put in question, however, by some 
national data. Recent outbreaks of HIV among drug users 
in Greece and Romania, together with ongoing problems 
in some Baltic countries, have stalled Europe’s progress 
in reducing the number of new drug-related infections. 
In part, this seems to be associated with the replacement 
of heroin by other substances, including synthetic opioids 
and stimulants. In addition, the absence of sufficient 
demand reduction interventions, particularly treatment 
12
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I New psychoactive substances: no signs of abating
Most overdoses occur among individuals who have 
consumed multiple substances, and attributing causality 
is often problematic. With the continuing release of new 
psychoactive substances on the drug market, there is 
concern that new or obscure substances that have 
contributed to deaths may escape detection. The high 
potency of some synthetic substances further complicates 
their detection, as they will be present only at very low 
concentrations in the blood. The emergence of highly 
potent synthetic substances also has implications for law 
enforcement, as even small quantities of these drugs can 
be converted into multiple doses (Figure).
In 2013, 81 new psychoactive substances were notified to 
the EU Early Warning System, bringing the number of 
substances monitored to more than 350. Formal risk 
assessments are launched for substances suspected of 
causing significant harm at the European level. Risk 
assessments were carried out on two substances in 2013, 
and on a further four by April 2014, with more expected. 
This means that at a time when new EU legislation in this 
area is being discussed, the Early Warning System is 
coming under increasing pressure from the volume and 
variety of substances appearing on the market.
Central to the work of the Early Warning System are 
reports on adverse events, principally deaths and acute 
intoxications. However, robust monitoring systems for 
drug-related health emergencies exist in only a few 
countries. Standardised reporting on this topic does not 
take place at EU level and the lack of systematic 
availability, and harm reduction measures is also likely to 
be an important contributory factor. Worryingly, a recent 
EMCDDA–ECDC risk assessment exercise also identified a 
number of other European countries where behavioural or 
response indicators suggested a potential elevated risk for 
future harms and health problems.
I  Multiple substances identified in  drug-induced deaths
Drug overdose remains a major cause of avoidable 
mortality among young Europeans, in recent years, 
however, progress has been made in reducing this 
problem. In part, this can be explained by both a scaling-up 
in responses and by declines in contributory risk 
behaviours. In contrast to the overall trends, in a number of 
countries, mostly in the north of Europe, overdose deaths 
remain relatively high, and are increasing. 
While deaths related to heroin are generally falling, deaths 
related to synthetic opioids are increasing, and in some 
countries now exceed those attributed to heroin. 
Exceptionally high rates of drug overdose deaths reported 
by Estonia, for example, are associated with the use of 
fentanyls, a family of highly potent synthetic opioids. In 
2013, the EMCDDA continued to receive reports of both 
controlled and non-controlled fentanyls appearing on the 
European drug market. Among the drugs reported to the 
EU Early Warning System in 2013 was a fentanyl never 
previously noted on the EU drug market. These substances 
pose a challenge for identification, as they may be present 
in toxicological samples in very small quantities.
HOW MUCH PURE DRUG IS NEEDED TO MAKE 10 000 DOSES?
 New drugs   ‘Old’ drugs
MDMA
750 g
Cocaine
200 g
Amphetamine
100 g
PB-22
100 g
25I-NBOMe
5 g
2-Methylfentanyl
2.5 g
Carfentanil
0.1 g
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At a glance — estimates of drug use in the European Union
Cannabis
73.6 million or 21.7 % of adults (15–64) used cannabis in their 
lifetime
18.1 million or 5.3 % of adults (15–64) used cannabis in the last 
year
14.6 million or 11.2 % of young adults (15–34) used cannabis in 
the last year
0.4 % and 18.5 % — lowest and highest national estimates of 
last year cannabis use among young adults
Cocaine
14.1 million or 4.2 % of adults (15–64) used cocaine in their 
lifetime
3.1 million or 0.9 % of adults (15–64) used cocaine in the last 
year
2.2 million or 1.7 % of young adults (15–34) used cocaine in the 
last year
0.2 % and 3.6 % — lowest and highest national estimates of last 
year cocaine use among young adults
Amphetamines 
11.4 million or 3.4 % of adults (15–64) used amphetamines in 
their lifetime
1.5 million or 0.4 % of adults (15–64) used amphetamines in the 
last year
1.2 million or 0.9 % of young adults (15–34) used amphetamines 
in the last year
0.0 % and 2.5 % — lowest and highest national estimates of last 
year amphetamines use among young adults
Ecstasy 
10.6 million or 3.1 % of adults (15–64) used ecstasy in their 
lifetime
1.6 million or 0.5 % of adults (15–64) used ecstasy in the last 
year
1.3 million or 1.0 % of young adults (15–34) used ecstasy in the 
last year
0.1 % and 3.1 % — lowest and highest national estimates of last 
year ecstasy use among young adults
Opioids
1.3 million problem opioid users (15–64)
3.5 % of all deaths of Europeans 15–39 years old are drug 
overdoses, opioids are found in about three-quarters of fatal 
overdoses
Principal drug in about 45 % of all drug treatment requests in the 
European Union
700 000 opioid users received substitution treatment in 2012
NB: For the complete set of data and information on the methodology see the 
accompanying online European Drug Report: Data and statistics.
monitoring in this area represents a blind spot in Europe’s 
surveillance of emerging health threats. An example of this 
is the difficulties in determining the implications at 
European level of reports from some countries of severe 
reactions to the use of synthetic cannabinoids.
I  Cannabis: controversies, contrasts and contradictions
Attitudinal data from the European Union suggests that 
cannabis is the drug where public opinion remains most 
polarised. This contributes to a lively public debate, which 
has recently been fuelled by international developments in 
the way cannabis availability and use is controlled, notably 
regulatory changes in parts of the United States and Latin 
America.
In Europe, in contrast to elsewhere, the overall use of 
cannabis appears to be stable or even declining, especially 
in younger age groups. The picture, however, is not 
uniform. A number of generally low-prevalence countries 
have observed recent increases in use.
In contrast to a policy debate characterised by discussion 
of regulatory options, practice developments primarily 
focus on measures to respond to the social problems and 
harms associated with cannabis production and use. The 
health implications of different patterns of cannabis use 
are becoming better understood. The availability and 
uptake of treatment for cannabis problems has increased, 
although the number of cannabis clients entering 
specialised drug treatment has stabilised. Cannabis is now 
the most commonly reported drug for receiving help 
among clients entering treatment for the first time in their 
life. The understanding of what constitutes an effective 
response in this area is also growing, with countries 
investing in a broad range of services, from intensive 
support sessions involving family members to brief 
interventions delivered over the Internet.
Since about 2000, many countries have reduced the 
severity of penalties applied for simple use or possession 
offences. More generally, European discussions on 
cannabis control have tended to focus on targeting drug 
supply and trafficking rather than use. In contradiction to 
this, however, the overall number of possession and use 
offences related to cannabis has been steadily increasing 
for nearly a decade. 
14
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The increasingly dynamic, global and innovative nature of 
the modern drug market is also illustrated by the re 
emergence of high-quality ecstasy powders and pills in the 
European Union and elsewhere. This appears to result from 
illicit producers importing non-controlled or ‘masked’ 
chemicals for the manufacture of the drug. Recently, 
Europol noted the dismantling in Belgium of the two 
largest drug production sites ever found within the 
European Union, which were capable of rapidly producing 
large volumes of MDMA (3,4-methylenedioxy-
methamphetamine). Seizures and reports of adverse 
health events have also prompted Europol and the 
EMCDDA to release a joint warning on the availability of 
extremely high-potency products containing MDMA.
I A volatile stimulants market
It remains to be seen if the increases observed in the 
MDMA content of ecstasy tablets will result in renewed 
consumer interest in this drug. The overall European 
market for illicit stimulants appears to be relatively stable, 
with cocaine remaining the stimulant of choice in southern 
and western countries and amphetamine more prevalent 
in northern and eastern countries. Indicators for both 
cocaine and amphetamine use are generally downward. 
The significance of geographical differences in Europe’s 
stimulant market is supported by new wastewater studies, 
which are increasingly capable of providing data on drug 
consumption behaviours at the city level and in specific 
settings. 
Availability is a key factor in stimulant consumption. 
Scarcity of a drug may cause consumers to try another 
substance, and price and perceptions of quality will be 
important considerations. This has been seen in 
recreational settings and among injecting drug users. 
A backdrop to this is the increasing number of products 
now available on the stimulants market, which includes 
synthetic cathinones, along with methamphetamine, 
amphetamine, ecstasy and cocaine. 
I  Drug production and supply: core business for organised crime 
The scale of the cannabis market combined with an 
increase in domestic production has led to a growing 
recognition of the importance of the drug as a cash 
generator for organised crime groups. Also now receiving 
more attention are the attendant social costs, which 
include violence and other forms of offending, and the 
strain that policing drug production places on law 
enforcement services. 
Both internationally and within the European Union, 
South-East Asian organised crime groups, among others, 
have been associated with cannabis production. 
Worryingly, there are signs that they are now diversifying 
into methamphetamine production and sale in parts of 
central Europe. This reflects a more general development 
noted in the recent EMCDDA–Europol analysis of the drug 
market: for crime groups to take a more multi-commodity, 
opportunistic and interlinked approach. This can be seen in 
the case of crime groups historically involved in the heroin 
trade, and now reported to be trafficking cocaine and 
methamphetamine in the European Union, using 
established heroin routes.
The 2014 report raises new concerns about the evidence 
of increasing availability of methamphetamine in Europe. 
As well as domestic production in central and northern 
Europe, this drug is also produced in the Middle East and 
sometimes imported into the European Union for re-export 
to South-East Asian countries. Increasingly, however, some 
of this production is contributing to availability within 
Europe. New reports of the emergence of the smoking of 
methamphetamine in Greece and Turkey are particularly 
worrying, given the potential health risks associated with 
the use of the drug in this way.
 The increasingly dynamic,  
 global and innovative nature  
 of the modern drug market  
 is also illustrated by the  
 re-emergence of high-quality  
 ecstasy powders and pills 
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I The long-term costs of treating drug problems
Europe faces the dual challenge of developing effective 
responses to emerging problems and continuing to 
address the needs of drug users in long-term treatment. 
This report highlights changes and the emergence of new 
patterns in epidemiology and responses. Nevertheless, the 
bulk of costs related to treating drug use continue to stem 
from problems that are rooted in the heroin ‘epidemics’ of 
the 1980s and 1990s. Although initiation into heroin use 
may be in decline, heroin dependence, characterised by a 
chronic disease model with cycles of relapse and 
treatment entry, remains a key focus for interventions. The 
European Union has invested considerably in providing 
treatment opportunities for this group, with an estimated 
three-quarters of a million currently in opioid substitution 
treatment. A strong argument can be made for the public 
health benefits of this intervention, and its contribution to 
weakening the illicit market. Europe is now faced with 
caring for an ageing cohort of current and former heroin 
users, many of whom are socially disadvantaged and 
excluded. In this context, there is growing policy interest 
in what constitutes recovery and social reintegration. 
Moreover, as this population ages, their vulnerabilities to 
a range of health problems are likely to increase.
 Around one million seizures  
 of illicit drugs are reported  
 annually in Europe 
1
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Drug supply
Europe is a major destination for 
controlled substances and also plays a 
more limited role as a transit point for 
drugs en route to other regions. Latin 
America, West Asia and North Africa are 
important source areas for drugs 
entering Europe. Europe is also a 
producing region for cannabis and 
synthetic drugs. Whereas virtually all 
cannabis produced in Europe is 
intended for local consumption, some 
synthetic drugs are also manufactured 
for export to other regions.
The availability of ‘new psychoactive 
substances’ that are not controlled 
under international drug control treaties 
represents a relatively new 
development in European drug markets. 
Commonly produced outside of Europe, 
these substances can be obtained 
through online retailers, specialised 
shops, and are also sometimes sold on 
to the illicit drug market.
Monitoring drug supply
Analysis in this section is based on a range of data 
sources: drug seizures, dismantled drug production 
facilities, seizures of precursor chemicals, drug 
supply offences, retail drug prices, and forensic 
analyses of drug seizures. Full data sets and 
methodological notes can be found in the online 
European Drug Report: Data and statistics. It should 
be noted that trends can be influenced by a range of 
factors, which include law enforcement activity levels 
and the effectiveness of interdiction measures.
Data on new psychoactive substances are based on 
notifications to the EU Early Warning System, which 
relies on data provided by the EMCDDA’s and 
Europol’s national networks. A full description of this 
mechanism can be found on the EMCDDA website 
under Action on new drugs.
I 80 % of seizures in Europe are for cannabis 
Around one million seizures of illicit drugs are reported 
annually in Europe. Most of these are small quantities of 
drugs confiscated from users, although this total also 
includes multi-kilogram consignments seized from 
traffickers and producers. 
In 2012, two-thirds of all seizures in the European Union 
were reported by just two countries, Spain and the United 
Kingdom. Smaller, but non-trivial numbers of seizures were 
reported by Germany, Belgium, Italy and four Nordic 
countries (Figure 1.1). It should be noted that recent data 
are not available for three countries that reported sizeable 
Chapter 1
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I Cannabis: increasing availability of herbal products
Two distinct cannabis products are commonly found on the 
European drugs market: herbal cannabis (‘marijuana’) and 
cannabis resin (‘hashish’). The annual consumption of these 
products can be roughly estimated at around 2 000 tonnes. 
Herbal cannabis found in Europe is both cultivated 
domestically and trafficked from external countries. Most 
cannabis resin is imported by sea or by air from Morocco.
Over the past ten years, the number of herbal seizures has 
overtaken that of resin, and now represents almost 
two-thirds of all cannabis seizures (Figure 1.2). This 
reflects the growing availability of domestically produced 
herbal cannabis in many countries. The quantity of 
cannabis resin seized in the European Union, although 
falling in recent years, is still much higher than the quantity 
of herbal cannabis reported (457 tonnes versus 
105 tonnes in 2012). This is probably explained by the fact 
that cannabis resin is more likely to be moved in volume 
across greater geographical distances and across borders, 
and is therefore more vulnerable to interdiction.
In terms of quantities seized, a small number of countries 
are disproportionately important, in part because of their 
location on major trafficking routes (Figures 1.2 and 1.3). 
Spain, for example, with its close proximity to Morocco, 
and substantial internal market, reported around 
numbers of seizures in the past. In addition, Turkey is an 
important country for drug seizures, with some of the 
drugs intercepted being intended for consumption in other 
countries, both in Europe and in the Middle East. 
Over 80 % of seizures in Europe are for cannabis 
(Figure 1.1), reflecting its relatively high prevalence of use. 
Cocaine ranks second overall, with about double the 
number of seizures reported for either amphetamines or 
heroin. The number of ecstasy seizures is lower, but has 
been increasing in recent years. 
FIGURE 1.1
Number of reported seizures by country (left), and proportion of seizures for the main drugs (right), 2012
Seizures (000s)   <1   1–10   11–100   >100   No data
NB: Numbers of seizures (in thousands) for the ten countries with highest values.
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CANNABIS
240 000 seizures 395 000 seizures457 tonnes seized 105 tonnes seized
258 000 seizures  (EU + 2) 457 000
seizures  
(EU + 2)486
tonnes seized  
(EU + 2) 230
tonnes seized  
(EU + 2)
EU + 2 refers to EU Member States, Turkey and Norway. Price and potency of 
cannabis products: national mean values – minimum, maximum and interquartile 
range (IQR). Countries covered vary by indicator.
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59 % of reported supply offences
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FIGURE 1.2
Number of cannabis seizures, and quantity seized in tonnes: resin and herb, 2002–12
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two-thirds of the total quantity of resin seized in Europe in 
2012. In respect to herbal cannabis, both Greece, and Italy 
reported recent large increases in quantities seized. 
Since 2007, Turkey has seized larger quantities of herbal 
cannabis than any of the EU Member States, and 
the amount reported in 2012 was more than double that 
reported in 2011.
Seizures of cannabis plants can be regarded as an 
indicator of domestic production, although the quality 
of data available in this area poses problems for purposes 
of comparison. In 2012, 33 000 seizures of cannabis 
plants were reported in Europe. Between 2011 and 2012, 
reports of numbers of cannabis plants seized increased 
from 5 million to 7 million, largely accounted for by a 
quadrupling of seizures reported from Italy. During the 
same period, quantities seized increased from 33 tonnes 
to 45 tonnes. 
FIGURE 1.3
Quantity of cannabis resin and herbal cannabis seized, 2012
326 10
51 3
2 5
2
22 21
27 125
13 13
6
12 13
16
22
Tonnes   <1   1–10   11–100   >100
NB: Amounts seized (in tonnes) for ten countries with highest values.
Resin Herb
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European-level indexed trends show increases in both the 
retail price and the potency (level of tetrahydrocannabinol, 
THC) of herbal cannabis and cannabis resin between 2006 
and 2012. The potency of both forms of cannabis has 
increased since 2006, though, for resin, much of the 
increase is observed between 2011 and 2012. 
The emergence of synthetic cannabinoids, chemicals that 
mimic the effects of cannabis, has added a new dimension 
to the cannabis market. Most synthetic cannabinoid 
powders appear to be manufactured in China, and are 
then shipped in bulk, using established legitimate 
transport and distribution networks. Once in the European 
Union, the chemicals are typically mixed with or sprayed 
onto herbs and packaged as ‘legal high’ products for sale 
either on the Internet or via other retailers. In the first six 
months of 2013, eighteen countries reported more than 
1 800 seizures of synthetic cannabinoids. The largest 
seizures were reported by Spain (20 kg) and Finland (7 kg). 
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I  Heroin: overall decline in seizures,  but increases in Turkey
Two forms of imported heroin have historically been 
available in Europe: the more common of these is brown 
heroin (its chemical base form), originating mainly from 
Afghanistan. Far less common is white heroin (a salt form), 
which historically came from South-East Asia, but now 
may be produced elsewhere. Some limited production of 
opioid drugs also still takes place in Europe, principally 
homemade poppy products reported in parts of eastern 
Europe. 
Afghanistan remains the world’s largest illicit producer of 
opium, and most heroin found in Europe is thought to be 
manufactured there or, to a lesser extent, in neighbouring 
Iran or Pakistan. The drug may enter Europe by a number 
of trafficking routes. One of these routes runs through 
Turkey, into Balkan countries (Bulgaria, Romania or 
Albania) and on to central, southern and western Europe. 
Another route runs through Russia, via the former Soviet 
republics of Central Asia. Heroin shipments from Iran and 
HEROIN
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Pakistan may also enter Europe by air or sea, either directly 
or transiting through west and east African countries. 
Between 2002 and 2010, the number of heroin seizures 
reported in Europe was relatively stable, with annual levels 
at around 50 000. However, since 2010, the number of 
heroin seizures has decreased considerably, with an 
estimated 32 000 seizures reported in 2012. The quantity 
of heroin seized in 2012 (5 tonnes) was the lowest 
reported in the last decade, and equivalent to only half of 
the quantity seized in 2002 (10 tonnes). Declining seizures 
in the European Union have been accompanied by 
 Since 2010, the number of  
 heroin seizures has  
 decreased considerably,  
 with an estimated 32 000  
 seizures reported in 2012 
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FIGURE 1.4 FIGURE 1.5
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I Cocaine: number of seizures continues to decline
In Europe, cocaine is available in two forms, the most 
common of which is cocaine powder (a hydrochloride salt, 
HCl). Less commonly available is crack cocaine, 
a smokeable form of the drug. Cocaine is produced from 
the leaves of the coca bush. The drug is produced almost 
exclusively in Bolivia, Colombia and Peru, and is transported 
to Europe by both air and sea routes. Trafficking of cocaine 
into Europe — and law enforcement efforts against this 
trafficking — appears to take place mainly through western 
and southern countries, with Spain, Belgium, the 
Netherlands, France and Italy together accounting for 85 % 
of the 71 tonnes seized in 2012 (Figure 1.6). Signs of the 
ongoing diversification of cocaine trafficking routes into 
Europe include large individual seizures in ports in Bulgaria, 
Greece, Romania and Baltic countries. 
In 2012, around 77 000 seizures of cocaine were reported 
in the European Union, amounting to 71 tonnes of the drug 
being intercepted. The number of cocaine seizures 
reported in 2012 remains at a high level compared to 
2002. However, it has declined from an estimated peak of 
around 95 000 seizures in 2008. The quantity of cocaine 
increasing seizures in Turkey, where, each year since 2006, 
more heroin has been seized than in all EU countries 
combined (Figures 1.4 and 1.5). 
The decline seen in heroin seizures since 2010/11 is 
mirrored both in trends in purity data and supply offences 
related to the drug (see Chapter 4). A number of countries 
experienced significant market shortages at this time, from 
which few markets appear to have fully recovered. In 
Turkey, however, the quantities of heroin seized decreased 
in 2011, before returning to higher levels in 2012.
Synthetic opioids that can be used as alternatives to 
heroin have been reported to the EU Early Warning 
System. These include the highly potent fentanyls, which 
may be diverted from pharmaceutical supplies, including 
inadequately disposed analgesic patches, or they may be 
manufactured specifically for the illicit market. Between 
2012 and 2013, 28 seizures were reported of a new 
synthetic opioid, AH-7921, which is similar to morphine in 
terms of pharmacology (see page 28). 
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FIGURE 1.6 FIGURE 1.7
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seized in 2012 increased by around 10 tonnes over the 
previous year, but is still well below the peak of 120 tonnes 
seized in 2006 (Figure 1.6). Decreases in the quantity of 
cocaine seized are most observable in the Iberian 
COCAINE
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80 000 seizures (EU + 2)72
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Peninsula, particularly in Portugal between 2006 and 
2007, and more gradually in Spain between 2006 
and 2011. Record seizures of cocaine were reported in 
2012 by Belgium (19 tonnes) (Figure 1.7). 
5.6
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for distribution within the country. In the last two years, 
there have been signs of increased involvement of 
Vietnamese organised crime groups in Czech 
methamphetamine markets and scaling-up of production. 
In 2011, there were 350 reports of dismantled 
methamphetamine production sites in Europe, most of 
these, however, were small-scale sites reported by the 
Czech Republic (338).
In 2012, 29 000 seizures of amphetamine were reported 
by Member States, amounting to 5.5 tonnes. More than 
half of the total quantity of amphetamine seized was 
accounted for by Germany, the Netherlands and the United 
Kingdom (Figure 1.8). After a period of higher levels, both 
in terms of numbers and quantity, amphetamine seizures 
in 2012 have returned to about the same level found in 
2003 (Figure 1.9). Methamphetamine seizures, though still 
small in number and quantity, have increased over the 
same period (Figure 1.10). In 2012, 7 000 seizures 
amounting to 0.34 tonnes of methamphetamine were 
reported in the European Union. A further 4 000 seizures 
amounting to 0.64 tonnes were reported by Turkey and 
Norway, which together reported about twice the amount 
seized in the European Union.
I  Amphetamines: signs of increased production of methamphetamine
Amphetamine and methamphetamine are closely related 
synthetic stimulants, generically known as amphetamines. 
Of the two, amphetamine has always been the more 
common in Europe, but there have been recent signs of 
the increasing availability of methamphetamine. 
Both drugs are manufactured in Europe for domestic use, 
although some amphetamine is also manufactured for 
export, principally to the Middle East. Production of 
amphetamine is known to take place in Belgium and the 
Netherlands, as well as in Poland and in the Baltic 
countries. For methamphetamine production, two main 
areas can be identified. First, in the Baltic States, 
production is centred around Lithuania for export to 
Norway, Sweden and the United Kingdom. In this region, 
BMK (benzyl methyl ketone) is used as a principal 
precursor. In a second area, focused around the Czech 
Republic and neighbouring countries Slovakia and 
Germany, production is mainly based on ephedrine and 
pseudoephedrine and takes place in small-scale so-called 
kitchen laboratories. Here, the output is destined primarily 
AMPHETAMINES
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FIGURE 1.8
Quantity of amphetamine and methamphetamine seized, 2012
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I Ecstasy: high purity powder available
Ecstasy usually refers to the synthetic substance MDMA 
(3,4-methylenedioxy-methamphetamine), which is 
chemically related to amphetamines, but which differs to 
some extent in its effects. Tablets sold as ecstasy, however, 
may contain any of a range of MDMA-like substances and 
unrelated chemicals. Both MDMA powder and crystals 
appear to be becoming more common, and high purity 
powder is available in parts of Europe.
Production of ecstasy in Europe appears to be 
concentrated in Belgium and the Netherlands, as 
evidenced by the number of laboratories dismantled in 
these countries over the last decade. The number of 
ecstasy laboratories dismantled in Europe fell from 50 in 
2002 to three in 2010, suggesting a large decrease in 
production of the drug. More recently, there have been 
signs that the ecstasy market is recovering, with several 
large MDMA production sites dismantled in Belgium and 
the Netherlands in 2013.
In 2012, 4 million ecstasy tablets were seized in the 
European Union, mainly in the Netherlands (2.4 million), 
followed by the United Kingdom (0.5 million) and Germany 
(0.3 million). In addition, Turkey seized 3.0 million ecstasy 
tablets in the same year (Figures 1.11 and 1.12). The 
quantity of ecstasy tablets seized in the European Union in 
2012 represents less than one-fifth of the quantity seized 
in 2002 (23 million). Overall, seizures of ecstasy decreased 
between 2002 and 2009, before increasing slowly in 
subsequent years (Figure 1.11). This trend is also mirrored 
in the data available on the MDMA content of analysed 
ecstasy tablets, which decreased until 2009, and 
increased in the last three reporting years. 
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I Cathinones, a new class of stimulants in Europe
In recent years, more than 50 substituted cathinone 
derivatives have been identified in Europe. The best known 
example, mephedrone, has established itself on the 
stimulants market in some countries. Another cathinone, 
MDPV (3,4-methylenedioxypyrovalerone), is sold on the 
European market predominantly in powder and tablet form 
as a ‘legal high’, but also directly on the illicit market. More 
than 5 500 seizures of MDPV powder have been reported 
from 29 countries between 2008 and 2013, amounting to 
over 200 kilograms of the drug.
I Increasing diversity in new drugs identified
Analysis of the drug market is complicated by the 
emergence of new drugs (new psychoactive substances) 
— synthetic or naturally occurring substances that are not 
controlled under international law, and often produced 
with the intention of mimicking the effects of controlled 
drugs. In some cases, new drugs are produced in Europe in 
clandestine laboratories and sold directly on the market. 
Other chemicals are imported from suppliers, often in 
China or India, and then attractively packaged and 
marketed as ‘legal highs’ in Europe. The term ‘legal highs’ 
is a misnomer, as substances may be controlled in some 
Member States, or if sold for consumption, contravene 
consumer safety or marketing regulations. To avoid 
Trends observed in ecstasy supply may, in part, be 
attributed to strengthened controls and the targeted 
seizure of PMK (piperonyl methyl ketone), the main 
precursor chemical for the manufacture of MDMA. Ecstasy 
producers have reportedly responded to precursor controls 
by using ‘pre-precursors’ or ‘masked precursors’ — 
essential chemicals that can be legally imported as 
non-controlled substances and then converted into the 
precursor chemicals necessary for MDMA production. 
FIGURE 1.11 FIGURE 1.12
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I Assessing the risk of new drugs 
European-level risk assessments were undertaken on 
4-methylamphetamine (in 2012) and 5-(2-aminopropyl)
indole (in 2013), in response to emerging evidence of 
harms that included over 20 fatalities associated with each 
substance over a short period of time. Both of these 
substances were subjected to control measures 
throughout Europe. Four new psychoactive substances 
(25I-NBOMe, AH-7921, MDPV, methoxetamine) were 
risk-assessed in April 2014.
25I-NBOMe is a substituted phenethylamine and a potent 
full agonist of the serotonin 5-HT2A receptor, which 
appears to have hallucinogenic effects. It has been 
available on the EU drug market since at least May 2012. 
Severe toxicity associated with its use has been reported 
in four Member States, including one death where the 
substance was detected.
AH-7921 is a synthetic opioid, which has been available in 
the European Union since at least July 2012. In most 
cases, it has been seized in small quantities as a powder. 
This opioid has been detected in six non-fatal intoxications 
and fifteen deaths in Sweden, the United Kingdom and 
Norway. 
MDPV is a synthetic cathinone derivative closely related to 
pyrovalerone. MDPV has been present in the EU drug 
market since at least November 2008, and has been 
detected in up to 107 non-fatal intoxications and 99 
deaths, particularly in Finland and the United Kingdom. 
There are some indications that it has been sold as a ‘legal’ 
or synthetic version of cocaine, and it has also been found 
in tablets resembling ‘ecstasy’. 
Methoxetamine is an arylcyclohexylamine closely related 
to ketamine, and has been available on the EU drug market 
since at least September 2010. Multi-kilogram quantities 
of the substance in powder form have been seized. Twenty 
deaths and 110 non-fatal intoxications associated with the 
substance have been reported.
New psychoactive substances can appear on the market 
either under the guise of a controlled drug, or as an 
alternative to a controlled drug. For example, 
4-methylamphetamine was sold directly on the illicit drug 
market as amphetamine, methoxetamine is marketed 
as a legal alternative to ketamine and 25I-NBOMe is sold 
as a ‘legal’ alternative to LSD (lysergic acid diethylamide).
controls, products are often mislabelled, for example as 
‘research chemicals’ or ‘plant food’ with disclaimers that 
state the product is not intended for human consumption. 
During 2013, 81 new psychoactive substances were 
notified by the Member States for the first time through the 
EU Early Warning System (Figure 1.13). Twenty-nine of 
these substances were synthetic cannabinoids and 
another 30 compounds did not conform to the readily 
recognised chemical groups (including plants and 
medicines). There were also 13 new substituted 
phenethylamines reported, seven synthetic cathinones, 
a tryptamine and a piperazine.
FIGURE 1.13
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I The Internet as a growing marketplace
The Internet is playing a growing role in shaping how drugs 
are being sold and poses unique challenges to disrupting 
the supply of both ‘new’ and ‘old’ drugs. The fact that 
manufacturers, suppliers, retailers, website-hosting and 
payment processing services may all be based in different 
countries makes it particularly difficult to control. The 
growing use of anonymising networks — so-called 
‘darknets’ — for the sale of drugs to dealers and 
consumers adds to these challenges. The technology 
to access these sites is increasingly being incorporated 
into consumer software, opening up these marketplaces 
to more people. In addition, the open sale of ‘legal highs’ 
on the Internet appears to have increased their availability 
to distributors and consumers. In 2013, EMCDDA 
monitoring identified 651 websites selling ‘legal highs’ to 
Europeans.
I More medicines detected
A growing number of new drugs that are detected on the 
drug market have legitimate use as medicines. Sometimes 
they are sold as medicines, in other cases they are sold 
clandestinely as illicit drugs such as heroin, or they may be 
sold as ‘legal highs’, ‘research chemicals’, and even as 
‘food supplements’. Recent examples, all reportedly 
injected by opioid users include: pregabalin, used for 
treating neuropathic pain, epilepsy and generalised 
anxiety; tropicamide, used during eye examinations to 
dilate the pupils; and carfentanil, an opioid used to 
tranquillise large animals. 
FOUR SUBSTANCES RISK-ASSESSED IN 2014
Other medicinal products recently reported to the Early-
warning system include: phenazepam, a benzodiazepine, 
which has been sold as a ‘legal’ benzodiazepine, as a 
‘research chemical’ and as the controlled drug diazepam; 
and, phenibut, an anxiolytic used to treat alcohol 
dependency in Russia, which has been sold online as a 
‘food supplement’. These medicines may be sourced in a 
number of ways: licensed medicines can be diverted from 
the regulated market and unlicensed medicines can be 
imported from outside the European Union. In addition, the 
component drugs can be imported in bulk from countries 
such as China, then processed and packaged in European 
countries and sold directly on the illicit drug market, on the 
‘legal highs’ market, or on e-commerce sites.
MDPV Methoxetamine AH-7921 25I-NBOMe Substance
Cathinones Arylcyclohexylamines Opioids Phenethylamines Drug family
2008 2010 2012 2012
Year of first notification  
to the EU Early Warning System
99 20 15 1
Number of deaths associated  
with the substance
107 110 6 15
Number of non-fatal  
intoxications
29 24 8 24
Number of countries where it has been  
detected (EU, Turkey and Norway)
22 9 1 6
Number of countries where it is subject  
to control measures under drug control  
legislation (EU, Turkey and Norway)
 A growing number of new  
 drugs that are detected on  
 the drug market have  
 legitimate use as medicines 
N
O
O
O O
N
H
O
N
O
N
H
Cl
Cl N
O
O
H
I
O
30
European Drug Report 2014: Trends and developments
EMCDDA and Europol joint publications
2014
Annual Report on the implementation of Council 
Decision 2005/387/JHA.
EMCDDA–Europol Joint Report on a new 
psychoactive substance: AH-7921 (3,4-dichloro-N-[[1-
(dimethylamino)cyclohexyl]methyl]benzamide).
EMCDDA–Europol Joint Report on a new 
psychoactive substance: methoxetamine 
(2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone).
EMCDDA–Europol Joint Report on a new 
psychoactive substance: 25I-NBOMe (4-iodo-2,5-
dimethoxy-N-(2-methoxybenzyl)phenethylamine).
EMCDDA–Europol Joint Report on a new 
psychoactive substance: MDPV 
(3,4-methylenedioxypyrovalerone).
2013
Annual Report on the implementation of Council 
Decision 2005/387/JHA.
EU Drug markets report: a strategic analysis.
Amphetamine: a European Union perspective in the 
global context.
2010
Cocaine: a European Union perspective in the global 
context.
2009
Methamphetamine: a European Union perspective in 
the global context.
All publications are available at  
www.emcdda.europa.eu/publications
FIND OUT MORE
EMCDDA publications
2014
New developments in Europe’s cannabis markets, 
Perspectives on drugs.
Exploring methamphetamine trends in Europe, 
EMCDDA Papers.
2013
Report on the risk assessment of 
4-methylamphetamine in the framework of the 
Council Decision on new psychoactive substances, 
Risk assessments.
Report on the risk assessment of 5-(2-aminopropyl)
indole in the framework of the Council Decision on 
new psychoactive substances, Risk assessments.
Synthetic cannabinoids in Europe, Perspectives on 
drugs.
Synthetic drug production in Europe, Perspectives on 
drugs.
2012
Cannabis production and markets in Europe, Insights.
2011
Recent shocks in the European heroin market: 
explanations and ramifications, Trendspotter meeting 
reports.
Report on the risk assessment of mephedrone in the 
framework of the Council Decision on new 
psychoactive substances, Risk assessments.
Responding to new psychoactive substances, Drugs 
in focus.
2010
Risk assessment of new psychoactive substances: 
operating guidelines.
2007
Early-warning system on new psychoactive 
substances: operating guidelines.

 Almost a quarter of the adult  
 population in the European Union,  
 or over 80 million adults, are estimated  
 to have used illicit drugs at some  
 point in their lives 
2
33
Chapter 2
The term ‘drug use’ covers many 
different patterns of consumption that 
range across a continuum from one-off 
experimental use to habitual and 
dependent use. Different consumption 
patterns are associated with different 
levels of risk and harm. Overall, the risks 
that an individual will be exposed to 
through their use of drugs will be 
influenced by factors including the 
context in which drugs are used, the 
dose consumed, route of administration, 
co-consumption of other substances, 
number and length of drug 
consumption episodes and individual 
vulnerability. 
Monitoring drug use and drug-related 
problems
A common approach to monitoring drug use in 
Europe is provided by the EMCDDA’s five key 
epidemiological indicators. These data sets cover: 
surveys of use, estimates of problem use, drug-
related deaths, infectious diseases and drug 
treatment entry. Taken together they provide an 
important resource for the EMCDDA’s analysis of 
trends and developments. Technical Information on 
the indicators can be found online in the Key 
indicators gateway and in the European Drug Report: 
Data and statistics. 
I Over 80 million Europeans have used an illicit drug 
Almost a quarter of the adult population in the European 
Union, or over 80 million adults, are estimated to have 
used illicit drugs at some point in their lives. In most 
cases, they have used cannabis (73.6 million), with lower 
estimates reported for the lifetime use of cocaine 
(14.1 million), amphetamines (11.4 million) and ecstasy 
(10.6 million). Levels of lifetime use vary considerably 
between countries, from around one-third of adults in 
Denmark, France and the United Kingdom, to less than 
one in 10 in Bulgaria, Greece, Cyprus, Hungary, Portugal, 
Romania and Turkey.
Drug use and drug-related 
problems
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users of alcohol and tobacco. In the month prior to the 
survey, 19 % of students report smoking one or more 
cigarettes a day, with 4 % smoking more than 10 a day. 
Almost two-thirds of students report drinking alcohol at 
least once in the last month, with 20 % being intoxicated 
at least once in this period.
I Cannabis: divergent national trends
Cannabis is generally smoked and, in Europe, commonly 
mixed with tobacco. Patterns of cannabis use range from 
the occasional or experimental to the regular and 
dependent, with problems strongly associated with more 
frequent use and higher doses. 
Cannabis is the illicit drug most likely to be used by all age 
groups. An estimated 14.6 million young Europeans 
(15–34), or 11.2 % of this age group, used cannabis in the 
last year, with 8.5 million of these aged 15–24 (13.9 %). 
Cannabis use is generally higher among males, and this 
I Drug use among school students
Monitoring substance use among students provides an 
important window on current youth risk behaviours and a 
pointer to potential future trends. In Europe, the ESPAD 
study provides a valuable resource for tracking trends over 
time in substance use among 15- to 16-year-old school 
students. In the most recent data, from 2011, one in four 
15- to 16-year-olds is estimated to have ever used an illicit 
drug, although prevalence levels vary considerably 
between countries. Cannabis accounts for the vast 
majority of illicit drug use in this group, with about 24 % 
reporting lifetime use, 20 % use in the last year and 12 % 
use in the month prior to the survey. Compared to their 
female counterparts, male students were 1.5 times more 
likely to report last month cannabis use. 
Many of those reporting ever using cannabis have only 
used the substance once or twice. A minority of students, 
however, report more intensive patterns of use, with 
around 2 % of students reporting using the drug more than 
10 times in the month prior to the survey. 
The prevalence of use of illicit drugs other than cannabis is 
far lower, although in a few countries the use of ecstasy 
and amphetamines feature more prominently. Overall, 
around 7 % of students report lifetime use of more than 
one illicit drug. ESPAD also reports on the use of alcohol 
and tobacco. Both of these substances were more 
commonly used by students than cannabis, and those who 
had used cannabis were also more likely to be regular 
SUBSTANCE USE BY EUROPEAN SCHOOL STUDENTS AGED 15–16 (ESPAD, 2011) 
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difference is usually accentuated for more intensive or 
regular patterns of use. Current trends in use appear 
divergent, as illustrated by the fact that of the countries 
that reported new surveys since 2011, eight reported 
decreases and five reported increases in last year 
prevalence. Few national surveys currently report on use 
of synthetic cannabinoid receptor agonists; for those that 
do, prevalence levels are generally low.
A growing number of countries now have sufficient survey 
data to allow a statistical analysis of long-term time trends 
in cannabis use among young adults (15–34). In Denmark, 
Finland and Sweden, upward trends in last year cannabis 
use among young adults can be observed, although at 
different levels of prevalence (Figure 2.1). In contrast, 
prevalence rates in Norway have remained relatively stable. 
Interestingly, Germany, France and the United Kingdom 
have seen either a stable or falling trend in use in the last 
decade, having observed increases before this period. 
Spain also reported lower prevalence in the last decade. 
Together these four countries account for almost half of 
the EU population. Bulgaria and Italy, with shorter time 
series, both have upward trends. More recently, Italy has 
reported lower prevalence levels, although due to 
methodological issues the surveys are not directly 
comparable.
FIGURE 2.1
Last year prevalence of cannabis use among young adults (15–34): countries with statistically significant trends (left) and most recent data (right)
 Italy  Denmark  France  Spain 
 Finland  Germany  UK (England and Wales) 
 Bulgaria  Sweden 
Percent
30
25
20
15
10
5
0
1
9
9
0
1
9
9
1
1
9
9
2
1
9
9
3
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
1
2
0
1
3
30
25
20
15
10
5
0
2
0
1
2
2
0
1
0
Percent   <4.0   4.1–8.0   8.1–12.0   >12.0   No data
I Concern about cannabis users 
A minority of cannabis users consume the substance 
intensively. Daily or almost daily cannabis use is defined as 
use on 20 days or more in the last month. Following these 
criteria, just under 1 % of European adults are estimated to 
be daily or almost daily cannabis users. Over two-thirds of 
daily or almost daily cannabis users are aged between 15 
and 34 years, and in this age group over three-quarters are 
male. Among the countries providing data, the estimated 
percentage of daily or almost daily users among young 
adults (15–34) varies from 0.1 % in Slovakia to 4.4 % in 
Spain (Figure 2.2).
In 2012, cannabis was the drug most frequently reported 
as the principal reason for entering drug treatment by 
first-time clients. Having risen from 45 000 to 61 000 
between 2006 and 2011, the overall number of reported 
first-time treatment entrants stabilised in 2012 (59 000). 
Cannabis was the second most frequently reported drug 
among all entrants to treatment in 2012 (110 000). 
Considerable national variation can be seen, however, 
ranging from 2 % of all treatment entrants reporting 
primary cannabis use in Bulgaria to 66 % in Hungary. This 
heterogeneity might be explained by national differences 
in referral practices, legislation, the type of treatment 
services available and cannabis prevalence levels.
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I  Acute emergencies associated with cannabis and synthetic cannabinoid products 
Although rare, acute emergencies can occur after 
consuming cannabis, especially at high doses. In countries 
with higher prevalence levels, cannabis-related 
emergencies appear to be a growing problem. Recent 
increases in emergencies related to cannabis have been 
reported in the Czech Republic, Denmark and Spain. Most 
cannabis-related emergencies occur among young males, 
and are often associated with alcohol intoxication. 
Symptoms can include anxiety, psychosis or other 
psychiatric symptoms and, in most cases, hospitalisation 
is not required. An additional worrying development has 
been the emergence of synthetic cannabinoids. These 
substances can be extremely potent, but are not 
chemically similar to cannabis, and therefore may result in 
different and potentially more serious health 
consequences. Although our current understanding of the 
health implications of consuming these substances 
remains limited, there is increasing concern about reports 
of acute adverse consequences associated with their use.
FIGURE 2.2
Prevalence of daily and almost daily cannabis use among 
young adults (15–34)
Percent   <0.50   0.51–1.0   >1.0   No data
CANNABIS  USERS ENTERING TREATMENT
NB: Characteristics are for all treatment entrants with cannabis as primary 
drug. Trends are for first-time entrants with cannabis as primary drug. 
Countries covered vary by indicator.
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I Geographic variation in patterns of stimulant use
Cocaine, amphetamines and ecstasy are the most 
commonly used illicit stimulants in Europe, while some 
lesser-known substances, including piperazines (e.g. BZP, 
benzylpiperazine) and synthetic cathinones (e.g. 
mephedrone and MDPV), may also be used illicitly for their 
stimulant effects. High levels of stimulant use tend to be 
associated with specific dance, music and nightlife 
settings, where these drugs are often used in combination 
with alcohol. 
Survey data illustrate the geographical differences in 
stimulant use patterns in Europe. Cocaine is more prevalent 
in the south and west of Europe, amphetamines in central 
and northern countries, and ecstasy — albeit at low 
prevalence levels — in countries in the south and east 
(Figure 2.3). Data from wastewater analysis carried out in 
a European multi-city study also shows a difference in 
regional patterns of use. Relatively high concentrations of 
amphetamine were found in wastewater samples from 
a number of cities in the north and northwest of Europe, 
whereas the highest methamphetamine levels were found 
in cities in the Czech Republic and Slovakia (Figure 2.4).
FIGURE 2.3
Predominant stimulant drug by last year prevalence among 
young adults (15–34)
 Cocaine   Ecstasy   Amphetamines   No data
mg/1 000 population/day 0 10 50 100 200 300
FIGURE 2.4
Amphetamines in wastewater of selected European cities
NB: Mean daily amounts of amphetamines in milligrams per 1 000 population, from sampling over a one-week period in 2013.  
Source: Sewage Analysis Core Group Europe (SCORE).
MethamphetamineAmphetamine
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Considering longer term trends in use of cocaine, for 
Denmark, Spain and the United Kingdom, all countries 
reporting relatively high prevalence rates, declines are 
observable after a peak in 2008 (Figure 2.5). Most other 
countries show stable or declining trends. 
Decreases in cocaine use are also observable in the most 
recent data, with 11 out of the 12 countries with surveys 
between 2011 to 2013 reporting falls in prevalence.
I Cocaine: prevalence continues to decline
Cocaine powder is primarily sniffed or snorted, but is also 
sometimes injected, while crack cocaine is usually 
smoked. Among regular users, a broad distinction can be 
made between more socially integrated consumers, who 
may be using the drug in a recreational context, and more 
marginalised drug users, who use cocaine, often along 
with opioids, as part of a chronic drug problem. Regular 
cocaine use has been associated with cardiovascular, 
neurological and mental health problems, and with an 
elevated risk of accident and dependence. Cocaine 
injection and use of crack cocaine are associated with 
the highest health risks, including the transmission of 
infectious diseases.
Cocaine is the most commonly used illicit stimulant drug 
in Europe, although most users are found in a restricted 
number of countries. It is estimated that about 2.2 million 
young adults aged 15 to 34 (1.7 % of this age group) used 
cocaine in the last year. 
 Cocaine is the most  
 commonly used illicit  
 stimulant drug in Europe 
FIGURE 2.5
Last year prevalence of cocaine use among young adults (15–34): selected trends (left) and most recent data (right)
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number (2 300) of first-time treatment entrants in Europe 
reported primary crack cocaine use, with the United 
Kingdom accounting for around two-thirds of these, and 
Spain and the Netherlands most of the rest. 
Cocaine is also responsible for acute hospital admissions 
and deaths. The drug may also be a factor in some 
mortality attributed to cardiovascular problems. While data 
in this area are limited, 19 countries reported cocaine-
related deaths in 2012, with over 500 cases identified.
I Continued decline in cocaine treatment demand
Only four countries have relatively recent estimates of 
intensive or problem cocaine use, and these are difficult to 
compare, as the definitions used differ. In 2012, among the 
adult population, Germany estimated ‘cocaine-
dependency’ at 0.20 %, Italy produced an estimate of 
0.26 % for those ‘in need of treatment for cocaine use’, and 
in 2011, Spain estimated ‘high-risk cocaine use’ at 0.4 %. 
For 2010/11, the United Kingdom estimated crack cocaine 
use among the adult population in England at 0.49 %, 
although the majority of these were also opioid users. 
Cocaine was cited as the primary drug for 14 % of all 
reported clients entering specialised drug treatment in 
2012 (55 000), and 18 % of those entering treatment for 
the first time (26 000). Differences exist between 
countries, with around 90 % of all cocaine clients being 
reported by only five countries (Germany, Spain, Italy, 
Netherlands, United Kingdom). Together, these five 
countries account for just over half of the EU population. 
The number of clients entering treatment for the first time 
in their life for primary cocaine use has been decreasing in 
recent years, from a peak of 38 000 in 2008 to 26 000 in 
2012. Much of this decrease can be accounted for by a 
drop in numbers reported from Italy. In 2012, only a small 
 19 countries reported  
 cocaine-related deaths in  
 2012, with over 500 cases  
 identified 
COCAINE USERS ENTERING TREATMENT
NB: Characteristics are for all treatment entrants with cocaine/crack as 
primary drug. Trends are for first-time entrants with cocaine/crack as primary 
drug. Countries covered vary by indicator.
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An estimated 1.2 million (0.9 %) young adults (15–34) 
used amphetamines during the last year. Between 2007 
and 2012, annual prevalence estimates for young adults 
remained relatively low and stable in most European 
countries, with prevalence levels of 2.5 % or less in all 
reporting countries. Among the 12 countries with surveys 
since 2011, 11 reported decreasing amphetamine 
prevalence levels (Figure 2.6).
I  Amphetamines: use decreasing but health risks continue
Amphetamine and methamphetamine, two closely related 
stimulants, are both used in Europe, although 
amphetamine is by far the more commonly available. 
Methamphetamine consumption has historically been 
restricted to the Czech Republic and, more recently, 
Slovakia, although this is now changing. 
Both drugs can be taken orally and snorted, in addition 
injection is relatively common among problem drug users 
in some countries. Methamphetamine can also be smoked, 
but this route of administration has only recently been 
reported in Europe.
Adverse health effects linked with amphetamines use 
include cardiovascular, pulmonary, neurological and mental 
health problems, while as with other drugs, injection is a 
risk factor for infectious diseases. As with other stimulants, 
deaths related to amphetamines can be difficult to identify. 
However, small numbers are reported annually, usually by 
countries where prevalence levels are high. 
FIGURE 2.6
Last year prevalence of amphetamines use among young adults (15–34): selected trends (left) and most recent data (right)
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AMPHETAMINES USERS ENTERING TREATMENT
NB: Characteristics are for all treatment entrants with amphetamines as 
primary drug. Trends are for first-time entrants with amphetamines as primary 
drug. Countries covered vary by indicator. 
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I Amphetamines use: a multi-faceted phenomenon 
Both the Czech Republic and Slovakia report longer-term 
entrenched patterns of methamphetamine use, with the 
most recent estimates of problem use among adults 
(15–64) at around 0.42 % for the Czech Republic (2012) 
and 0.21 % in Slovakia (2007). Recently, indications of 
problem methamphetamine use have also been reported 
among high-risk drug users in some regions in Germany 
and in Greece, Cyprus, Latvia and Turkey. This includes 
worrying signs from southern European countries of crystal 
methamphetamine smoking among sub-populations of 
opioid injectors. In addition, new injection trends have 
been detected among small groups of men who have sex 
with men in some large European cities. 
Around 6 % of clients entering specialised drug treatment 
in Europe in 2012 report amphetamines as their primary 
drug (approximately 25 000 clients, of whom 10 000 
entered treatment for the first time in their life). Primary 
amphetamine users account for a sizeable proportion of 
reported first-time treatment entries only in Germany, 
Latvia and Poland, while methamphetamine is cited as 
the primary drug by a large proportion of first-time clients 
in the Czech Republic and Slovakia. Recent increases 
in first-time entrants for amphetamines are accounted 
for primarily by Germany and by increases in first-time 
methamphetamine clients in the Czech Republic and 
Slovakia.
23 %
24 %
34 %
19 %
42
European Drug Report 2014: Trends and developments
Bulgaria, which has an upward trend in prevalence since 
2005, this decline continues to be evident for the 12 
countries reporting surveys since 2011. Few users entered 
treatment for problems relating to ecstasy in 2012: ecstasy 
was mentioned as the primary drug by less than 1 % 
(around 550 clients) of reported first-time treatment 
entrants in Europe. 
I  Ecstasy use: low and stable trends in the general population
Ecstasy usually refers to the synthetic substance MDMA. 
The drug is commonly used in tablet form, but is also 
available in crystal or powder form; it is usually swallowed or 
snorted. Ecstasy use has historically been linked to the 
electronic dance-music scene, and is concentrated among 
young adults, particularly young males. Problems associated 
with use of this drug include acute hyperthermia and mental 
health problems. Ecstasy-related deaths are reported, but 
are rare.
It is estimated that 1.3 million young adults (15–34) used 
ecstasy in the last year (1.0 % of this age group), with 
national estimates ranging from under 0.1 % to 3.1 %. In 
Europe, consumption of the drug typically peaked in the 
early to mid-2000s, before declining (Figure 2.7). Between 
2007 and 2012, most countries have reported stable or 
declining trends in ecstasy use. With the exception of  Between 2007 and 2012,  
 most countries have  
 reported stable or declining  
 trends in ecstasy use 
FIGURE 2.7
Last year prevalence of ecstasy use among young adults (15–34): selected trends (left) and most recent data (right)
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Where they exist, national estimates of the prevalence of 
GHB and ketamine use in both adult and school 
populations remain low. Denmark reports last year 
prevalence of ketamine use at 0.3 % among young adults 
(15–34), with 0.8 % of 16- to 24-year-olds reporting last 
year ketamine use in the United Kingdom, a drop from a 
peak of 2.1 % in 2010. Targeted surveys in nightlife settings 
typically report higher levels of prevalence. Among UK 
respondents to a 2013 self-selecting Internet survey who 
were identified as regular clubbers, 31 % reported last year 
use of ketamine, and 2 % reported last year use of GHB. 
I Synthetic cathinones: injection a concern
Synthetic cathinones, such as mephedrone and MPDV, 
have now carved a space in the illicit stimulants market in 
some countries. The limited information available suggests 
that prevalence levels remain low. Repeat surveys that 
include cathinones are only available for the United 
Kingdom (England and Wales). In the most recent survey 
(2012/13), last year use of mephedrone among adults 
aged 16 to 59 was estimated at 0.5 %, a decrease from 
1.1 % in 2011/12 and 1.4 % in 2010/11. Results from a 
non-representative survey of regular clubbers in the United 
Kingdom also show a decrease in last year mephedrone 
use (from 19.5 % in 2011 to 13.8 % in 2012). 
The injection of cathinones, including mephedrone, MDPV 
and pentedrone, continues to be a concern and has been 
reported among diverse populations, including opioid 
injectors, drug treatment clients, prisoners and small 
populations of men who have sex with men. An increase in 
treatment demand associated with synthetic cathinone 
use problems has been reported in Hungary, Romania and 
the United Kingdom. In Romania, a higher share of 
first-time treatment entrants reported new psychoactive 
substances as primary drug (37 %) than reported heroin 
(21 %). There were an estimated 1 900 mephedrone users  
entering treatment in the United Kingdom in 2011/12, with 
more than half of them under the age of 18. 
I  Low level of use of hallucinogens, GHB and ketamine
A number of psychoactive substances with hallucinogenic, 
anaesthetic and depressant properties are available on the 
illicit drug market in Europe: these may be used on their 
own, alongside, or in place of other more common drugs. 
The overall prevalence levels of hallucinogenic mushrooms 
and LSD (lysergic acid diethylamide) use in Europe have 
been generally low and stable for a number of years. 
Among young adults (15–34), national surveys report last 
year prevalence estimates for the use of hallucinogenic 
mushrooms ranging from 0 % to 0.8 %, and for LSD from 
0 % to 0.7 %. 
Since the mid-1990s, recreational use of ketamine and 
gamma-hydroxybutyrate (GHB) has been reported among 
subgroups of drug users in Europe. Recognition is growing 
of the health problems related to these substances, for 
example, damage to the bladder associated with long-term 
ketamine use. Loss of consciousness, withdrawal 
syndrome and dependence are risks linked to use of GHB, 
with Belgium and the Netherlands reporting some 
requests for treatment. 
 A number of psychoactive  
 substances with  
 hallucinogenic, anaesthetic  
 and depressant properties  
 are available on the illicit  
 drug market in Europe 
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I Opioids: 1.3 million problem users
The illicit use of opioids remains responsible for a 
disproportionately large share of the morbidity and 
mortality resulting from drug use in Europe. The main 
opioid used in Europe is heroin, which may be smoked, 
snorted or injected. A range of other synthetic opioids, 
such as buprenorphine, methadone and fentanyl, are also 
available on the illicit market. Opioid use tends to be 
highest among marginalised populations in urban areas. 
Europe has experienced different waves of heroin 
addiction, the first affecting many western European 
countries from the mid-1970s onwards and a second wave 
affecting central and eastern Europe in the mid- to late 
1990s. Although trends have varied over the last decade, 
overall, new recruitment into heroin use now appears to be 
on the decline. 
The average annual prevalence of problem opioid use 
among adults (15–64) is estimated at around 0.4 %, the 
equivalent of 1.3 million problem opioid users in Europe in 
2012. At national level, prevalence estimates of problem 
opioid use vary between less than one and around eight 
cases per 1 000 population aged 15–64 (Figure 2.8). 
FIGURE 2.8
National estimates of last year prevalence of problem opioid use
Rate per 1 000   <2.50   2.51–5.0   >5.0   No data
NB: Data for Finland are from 2005 and for Ireland from 2006.
I Heroin: continued reductions in treatment demand
Clients using opioids mainly heroin, as their primary drug, 
represent 46 % of all drug users who entered specialised 
treatment in 2012 in Europe (180 000 clients), and around 
26 % of those entering treatment for the first time. The 
overall numbers of new heroin clients are declining in 
Europe, almost halving from a peak of 59 000 in 2007 to 
31 000 in 2012. Overall, it appears that recruitment into 
heroin use has decreased and that this is now impacting 
on treatment demand. 
I Opioids other than heroin: of increasing concern
In 2012, in the majority of European countries (17) more 
than 10 % of first-time opioid clients entering specialised 
treatment were misusing opioids other than heroin 
(Figure 2.9). These included methadone, buprenorphine 
and fentanyl. In some countries, these drugs now 
represent the most common form of opioid use. In Estonia, 
the majority of treatment entrants for opioids were using 
illicit fentanyl, while in Finland most opioid clients are 
reported to be primary misusers of buprenorphine.
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HEROIN USERS ENTERING TREATMENT
NB: Characteristics are for all treatment entrants with heroin as primary drug. 
Trends are for first-time entrants with heroin as primary drug. Countries 
covered vary by indicator.
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FIGURE 2.9
First-time entrants for opioids other than heroin: trends in numbers (left) and as percentage of all first-time entrants  
with opioids as primary drug (right)
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I Injecting drug use: long-term decline 
Injecting drug users are among those at highest risk of 
experiencing health problems from their drug use, such as 
blood-borne infections or drug overdoses. Injection is 
commonly associated with opioid use, although in a few 
countries, amphetamines injection is a major problem. 
Twelve countries have recent estimates of the prevalence 
of injecting drug use, ranging from less than one to 
approximately six cases per 1 000 population aged 15–64. 
Among clients entering specialised treatment, 38 % of 
opioid clients and 23 % of amphetamine clients report 
injecting the drug. Levels of injecting among opioid clients 
vary between countries, from less than 6 % in the 
Netherlands to 100 % in Lithuania. 
An analysis of time trends among clients entering 
treatment for the first time in Europe indicates that 
injecting as the main route of administration has fallen 
since 2006 (Figure 2.10). The proportion of new clients 
reporting having injected amphetamines, cocaine or 
opioids in the last month has also fallen over the same 
time period.
FIGURE 2.10
Prevalence of injecting in last month among treatment entrants: trends among new entrants (left) and national rates among all entrants (right)
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HIV-related mortality is the best documented indirect 
cause of death among drug users. The most recent 
estimate suggests that about 1 700 people died of HIV/
AIDS attributable to injecting drug use in Europe in 2010, 
and the trend is downward. Liver disease is also likely to 
account for considerable and increasing numbers of 
deaths among injecting drug users, mainly due to HCV 
infection, and often worsened by heavy alcohol use. 
I HIV: outbreaks impact on EU trend
The injection of drugs continues to play a major role in the 
transmission of blood-borne infectious diseases such as 
hepatitis C and, in some countries, HIV/AIDS. The latest 
figures show that the long-term decline in the number of 
new HIV diagnoses in Europe might be interrupted as a 
result of outbreaks among injecting drug users in Greece 
and Romania (Figure 2.11). In 2012, the average rate of 
newly reported HIV diagnoses attributed to injecting drug 
use was 3.09 per million population. Although the figures 
are subject to revision, there were 1 788 newly reported 
cases in 2012, slightly more than in 2011 (1 732), 
continuing the upward trend observed since 2010. 
Whereas in 2010, Greece and Romania contributed just 
over 2 % of the total number of newly reported diagnoses, 
by 2012 this figure had increased to 37 %. In other 
countries such as Spain and Portugal, which have 
experienced periods with high rates of infection in the 
past, trends in rates of newly reported diagnoses continue 
to decline. The situation is less positive, however, in 
Estonia, where the rate of new diagnoses remains high, 
and in Latvia, where annual rates have been increasing 
since 2009.
 HIV-related mortality  
 is the best documented  
 indirect cause of death  
 among drug users 
FIGURE 2.11
Newly diagnosed HIV cases related to injecting drug use: trends (left) and most recent data (right)
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I Hepatitis and other infections: major health issues 
Viral hepatitis, and in particular infection caused by the 
hepatitis C virus (HCV), is highly prevalent among injecting 
drug users across Europe. HCV antibody levels among 
national samples of injecting drug users in 2011–12 varied 
from 19 % to 84 %, with seven of the 11 countries with 
national data reporting a prevalence rate in excess of 50 % 
(Figure 2.12). Among countries with national trend data for 
the period 2007–12, declining HCV prevalence in injecting 
drug users was reported in Norway, while seven others 
observed an increase. 
Averaged across the 18 countries for which data are 
available for the period 2011–12, injecting drug use 
accounts for 64 % of all HCV diagnoses and 50 % of the 
acute diagnoses notified (where the risk category is 
known). For hepatitis B, injecting drug users represent 9 % 
of all diagnoses and 21 % of acute diagnoses notified. 
Drug use may be a risk factor for other infectious diseases 
including hepatitis A and D, sexually transmitted diseases, 
tuberculosis, tetanus and botulism. Outbreaks of anthrax 
infection, probably caused by contaminated heroin, are 
also sporadically reported in Europe. For example, between 
June 2012 and March 2013, 15 drug-related anthrax cases 
were reported, of which seven resulted in fatalities.
FIGURE 2.12
HCV antibody prevalence among injecting drug users, 2011/2012
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I  Overdose deaths: overall reduction, but increases in some countries 
Drug use is one of the major causes of mortality among 
young people in Europe, both directly through overdose 
(drug-induced deaths) and indirectly through drug-related 
diseases, accidents, violence and suicide. Most studies on 
cohorts of problem drug users show mortality rates in the 
range of 1–2 % per year, and it has been estimated that 
between 10 000 and 20 000 opioid users die each year in 
Europe. Overall, opioid users are at least 10 times more 
likely to die than their peers of the same age and gender. 
For female opioid users, in some countries, the risk of 
dying may be up to 30 times that of their peers. 
Drug overdose continues to be the main cause of death 
among problem drug users. Heroin or its metabolites are 
present in the majority of reported fatal overdoses, often in 
combination with other substances such as alcohol or 
benzodiazepines. In addition to heroin, other opioids are 
regularly found in toxicological reports. These include 
methadone, buprenorphine, fentanyls and tramadol, with 
some countries reporting that such substances are 
responsible for a substantial share of overdose deaths. 
In two countries, the number of methadone-related 
overdoses exceeds those related to heroin. In most 
of cases where methadone is identified, the victim is not 
in substitution treatment at the time of death, but has used 
diverted methadone in the context of polydrug use.
While drug-related deaths among the very young generate 
considerable concern, only 10 % of overdose deaths 
reported in Europe occur among those aged under 25 
years. Typically, those dying of drug overdoses are in their 
mid-thirties or older, and their average age at death is 
rising, suggesting an ageing cohort of problem opioid users. 
Most overdose deaths (78 %) are reported among men. 
For 2012, the average mortality rate due to overdoses in 
Europe is estimated at 17 deaths per million population 
aged 15–64. National mortality rates vary considerably and 
are influenced by factors such as patterns of drug use, 
particularly injecting use, the characteristics of drug-using 
populations and reporting practices. Rates of over 40 
0 10 20 30 50 100 %60 70 80 9040
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deaths per million were reported in six countries, with the 
highest rates reported in Norway (76 per million) and 
Estonia (191 per million) (Figure 2.13). Overdose deaths in 
Estonia have increased sharply, and illustrate the impact 
that different drug consumption patterns can have on 
national figures — in Estonia, overdose deaths are mostly 
related to the use of fentanyls, which are highly potent 
synthetic opioids.
DRUG-INDUCED DEATHS
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FIGURE 2.13
Drug-induced mortality rates among adults (15–64): selected trends (left) and most recent data (right)
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Most countries reported an increasing trend in overdose 
deaths from 2003 until 2008/09, when overall levels first 
stabilised and then began to decline. Overall, around 6 100 
overdose deaths were reported in 2012. This is similar to 
the number reported in 2011, and a decrease from the 
7 100 cases in 2009. Nevertheless, the situation varies for 
individual countries, with some still reporting increases. 
NB: Trends in the ten countries reporting the highest rates in 2011 or 2012.
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Chapter 3
Interventions designed to prevent, treat 
and reduce the harms related to drug 
use are reviewed in this chapter. 
The chapter considers whether 
countries have adopted common 
approaches, to what extent are they 
informed by evidence, and if service 
availability matches estimated needs.
Monitoring health and social responses
This chapter draws on annual national assessments 
provided by EMCDDA focal points. These are 
complemented by data on treatment demand, opioid 
substitution treatment and needle and syringe 
provision. Expert ratings provide supplementary 
information on the availability of services, where 
more formalised datasets are unavailable. The 
chapter is also informed by reviews of the available 
scientific evidence on the effectiveness of public 
health interventions.
Supporting information can be found on the 
EMCDDA website in the Health and social responses 
profiles, the European Drug Report: Data and 
statistics and the Best practice portal.
I  Drug prevention for vulnerable groups of young people
A range of prevention strategies are used to tackle drug 
use and drug-related problems. Environmental and 
universal approaches target entire populations, selective 
prevention targets vulnerable groups who may be at 
greater risk of developing drug use problems, and 
indicated prevention focuses on at-risk individuals. In this 
year’s report, the focus is on selective prevention, an 
approach for which there is growing evidence of 
effectiveness for programmes that focus on norm-setting, 
environmental restructuring, motivation, skills and 
decision-making. Many programmes, however, continue to 
be based on information provision, awareness-raising and 
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I  Reducing harm in nightlife settings: the need for an integrated approach
The association between nightlife settings and some 
patterns of high-risk drug and alcohol use is well known. 
Despite this, only a limited number of European countries 
report implementing prevention strategies in this area 
(Figure 3.2), and expert ratings suggest an overall 
decrease in activities between 2010 and 2013. 
At European level, standards produced by Club Health and 
Safer Nightlife offer guidance for the implementation of 
prevention programmes in recreational settings. With 
regard to reducing harms, positive results have been 
obtained from integrated, environmental prevention 
approaches, which include components such as 
responsible serving, the training of bar and security staff 
and cooperation with law enforcement agencies. 
A particular concern is the risk posed by young people 
driving home from nightlife venues after consuming 
alcohol and drugs. A recent review found that targeted 
media campaigns, together with the offer of free late night 
transport, can reduce the number of traffic accidents 
caused by drink-driving. However, interventions targeting 
drug-driving are uncommon.
counselling; approaches where the evidence of 
effectiveness is scarce. 
Two important target groups for selective prevention 
interventions are school students with academic and 
social problems and young offenders (Figure 3.1). Expert 
assessments suggested an increase in overall provision for 
both these groups between 2007 and 2010, although no 
further changes were observed in 2013.
For interventions targeting students, evidence suggests 
that strategies that improve school climate may lead to 
reductions in substance use. Approaches in this area 
include teacher training and measures to improve student 
participation and promote a positive school ethos. Other 
prevention approaches focusing on students aim to 
increase self-control and build social competences, while 
family-focused approaches aim to improve parenting skills.
For young offenders, the majority of countries now report 
the introduction of alternative measures to penal 
sanctions. One programme of note in this area is FreD, a 
set of manual-based interventions, which has now been 
implemented in 15 EU Member States. Evaluations of this 
programme have shown a fall in repeat offending rates. 
FIGURE 3.1
Availability of specific drug prevention interventions for selected vulnerable groups (expert ratings, 2012)
 Full/extensive   Limited/rare   Not available   No data
School students with social  
and academic problems
Young offenders
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I Preventing the spread of infectious diseases
Drug users, and particularly injecting drug users, are at risk 
of contracting infectious diseases through the sharing of 
drug use material and through unprotected sex. Preventing 
the transmission of HIV, viral hepatitis and other infections 
is therefore an important objective for European drug 
policies. For injecting opioid users, it is now well 
demonstrated that substitution treatment reduces 
reported risk behaviour, with some studies suggesting that 
the protective effect increases when combined with needle 
and syringe programmes.
The number of syringes distributed through specialised 
programmes has increased in Europe (26 countries), rising 
from 42.9 million syringes in 2007 to 46.0 million in 2012. 
At country level, a divergent picture is evident, with around 
half of countries reporting an increase in provision and half 
a decrease (Figure 3.3). Increases can be explained by the 
expansion of provision, sometimes from a low base. 
Decreases may be explained by either a fall in service 
availability or a drop in client numbers. Among the 12 
countries with recent estimates of numbers of injectors, 
the average number of syringes distributed per injecting 
drug user through specialised programmes in 2012 ranged 
from zero in Cyprus to more than 300 in Spain and Norway 
(Figure 3.4).
FIGURE 3.2 FIGURE 3.3
Availability of drug prevention interventions in nightlife settings 
(expert ratings, 2012)
Change in number of syringes distributed through specialised 
programmes between 2007 and 2012
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FIGURE 3.5
Summary indicators for potential elevated risk for HIV infections among injecting drug users
Outbreaks of new HIV infections among injecting drug 
users have been reported recently in Greece and Romania, 
as noted in Chapter 2. This prompted a risk assessment 
exercise to identify if other countries might be vulnerable 
to new HIV outbreaks. An overview of some top-level 
indicators of potential risk is provided in Figure 3.5. Based 
on this simple analysis, around one-third of the countries 
can be regarded as having some risk factors present, 
suggesting a need for continued vigilance and for 
consideration of increasing the coverage of HIV prevention 
measures. 
Prevention measures targeting the transmission of 
hepatitis C are similar to those for HIV. At the policy level, 
an increasing number of countries have adopted or are 
preparing specific hepatitis C strategies. Initiatives directed 
at testing and counselling injecting drug users about 
hepatitis C remain limited. Despite growing evidence of the 
effectiveness of hepatitis C antiviral treatment for infected 
injecting drug users, levels of provision remain low.
FIGURE 3.4
Number of syringes provided through specialised programmes per 
injecting drug user (estimate)
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 None of the following risk factors identified: increase in HIV case reports or prevalence of HIV or HCV; increase in transmission risk; low intervention coverage.
 Risk factors possibly present: subnational increase in HIV or HCV prevalence or transmission risk; consistent but non-significant rise at national level.
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I More than a million Europeans in drug treatment
It is estimated that at least 1.3 million people received 
treatment for illicit drug use in Europe during 2012. Opioid 
users represent the largest group undergoing treatment, 
while data on treatment entries (Figure 3.6) suggest that 
cannabis and cocaine users are the second and third 
largest groups entering treatment services, although there 
are differences observable between countries. 
Most treatment is provided in outpatient settings, such as 
specialised centres, general healthcare centres, including 
general practitioners’ surgeries, and low-threshold 
facilities. A sizeable proportion of drug treatment is also 
provided in residential settings, such as specialised 
residential treatment centres, therapeutic communities 
and hospital-based residential centres (e.g. psychiatric 
hospitals). A new and innovative approach to treatment is 
the provision of services via the Internet, allowing those 
seeking help with a drug problem to access treatment 
programmes from their own home.
Substitution treatment, typically combined with 
psychosocial interventions, is the most common treatment 
for opioid dependence in Europe. The available evidence 
supports this combined approach for keeping patients in 
treatment, as well as for reducing illicit opioid use, drug-
related harms and mortality. Psychosocial interventions 
are the main treatment modality used for stimulant-
dependent users, with studies suggesting that both 
cognitive-behavioural therapy and contingency 
management are associated with positive results. 
A growing number of countries now offer cannabis-specific 
treatments, with the available evidence supporting the use 
of a combination of cognitive-behavioural therapy, 
motivational interviewing and contingency management 
approaches. Some evidence supports the use of 
multidimensional family therapy for young cannabis users. 
I Preventing overdoses and drug-related deaths
Reducing fatal drug overdoses and other drug-related 
deaths remains a major challenge for public health policy 
in Europe. Targeted responses in this area focus either on 
preventing the occurrence of overdoses, or on improving 
the likelihood of surviving an overdose. Drug treatment, 
particularly opioid substitution treatment, prevents 
overdoses and reduces the mortality risk of drug users. 
Training in responding to overdoses with the distribution of 
the opioid antagonist drug naloxone can save lives in 
overdose situations. One type of intervention that aims 
both to reduce the occurrence of overdose and to increase 
the chance of surviving an overdose is the use of 
supervised consumption facilities. Six EU Member States 
and Norway currently provide such facilities — 73 in total. 
In the past three years, a number of facilities have been 
closed in the Netherlands, due to falling demand, while 
four new facilities were opened in Denmark and one in 
Greece. 
FIGURE 3.6
Percentage of clients entering specialised drug treatment services, 
by primary drug
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I  Substitution treatment: the main outpatient treatment modality 
Methadone is the most commonly prescribed substitution 
medication, received by up to two-thirds of substitution 
clients, while buprenorphine is prescribed to most of the 
remaining clients (about 20 %), and is the principal 
substitution medication in six countries (Figure 3.7). About 
6 % of all substitution treatments in Europe rely on the 
prescription of other substances, such as slow-release 
morphine or diacetylmorphine (heroin). 
An estimated 734 000 opioid users received substitution 
treatment in Europe in 2012. This figure is relatively stable 
when compared with 2011 (726 000), but higher than the 
630 000 estimate for 2007 (Figure 3.8). In 2012, five 
countries reported increases of more than 25 % in client 
numbers compared to the previous year’s estimate. The 
highest percentage increase was noted in Turkey (250 %), 
followed by Greece (45 %) and Latvia (28 %). The 
percentage increases in these three countries, however, 
occurred in the context of relatively low base numbers. In 
contrast, during the same period, Romania (−30 %) 
reported the largest percentage decrease in estimated 
client numbers. 
FIGURE 3.7
Predominant opioid substitution medication at national level (left) and as a proportion of substitution clients in Europe (right)
 Methadone   Buprenorphine   Methadone = buprenorphine
FIGURE 3.8
Trends in number of clients in opioid substitution treatment
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I  Treatment coverage: over half of opioid users are in substitution treatment
Coverage of opioid substitution treatment — the 
proportion of those in need receiving the intervention — is 
estimated at more than 50 % of Europe’s problem opioid 
users. This estimate needs to be treated with caution for 
methodological reasons, but in many countries a majority 
of opioid users are, or have been, in contact with treatment 
services. At national level, however, large differences in 
coverage rates still exist, with the lowest estimated rates 
(around 10 % or less) reported in Latvia, Slovakia and 
Poland (Figure 3.9). 
Treatment without substitution medication is provided to 
opioid users in all European countries. In the ten countries 
providing sufficient data, the coverage of treatment 
approaches not involving substitution medication is 
generally within the range of 3 % to 17 % of all problem 
opioid users, reaching over 50 % in Hungary (Figure 3.10).
FIGURE 3.9
Percentage of problem opioid users receiving substitution 
treatment (estimate)
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NB: Data displayed as point estimates and uncertainty intervals.
FIGURE 3.10
Percentage of problem opioid users receiving drug treatment 
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The evidence on the effectiveness of drug-free therapeutic 
communities is inconclusive, in part because of 
methodological difficulties in conducting treatment 
outcome research in this area. Most research on this 
subject in Europe is limited to observational studies, and 
conclusions are therefore necessarily tentative. Generally, 
however, these studies report positive treatment 
outcomes, associated with longer retention in treatment 
and treatment completion. Almost all of the observational 
studies report that therapeutic community residents show 
reductions in drug use and arrests, as well as 
improvements in quality of life measures.
Although, historically, residential treatment programmes 
have been exclusively drug-free, current data indicate that 
the provision of substitution medication as a component of 
residential treatment programmes for opioid users is 
increasing. Some level of integration of opioid substitution 
in residential drug treatment was reported by 18 of 25 
reporting countries (Figure 3.12).
I  Residential treatment: therapeutic community approaches predominate
In most European countries, residential treatment 
programmes form an important element of the treatment 
and rehabilitation options for drug users. A recent 
EMCDDA study identified 2 500 residential treatment 
centres in Europe, with over two-thirds of the facilities 
concentrated in six countries: Germany, Spain, Ireland, 
Italy, Sweden and the United Kingdom. Community-
residential facilities form the largest group (2 330), with 
17 countries reporting all of their residential facilities to be 
of this variety. In addition, 170 hospital-based residential 
treatment programmes were also identified across Europe.
The focus for many residential programmes is on health, 
personal and social functioning and enhanced quality of 
life. Residential programmes can be characterised by four 
main therapeutic approaches: the 12-step or Minnesota 
model; the therapeutic community approach; 
psychotherapy using cognitive behavioural therapy; and 
psychotherapy using other care models. Of these, the 
‘therapeutic community model’ is predominant in 15 
countries (Figure 3.11).
FIGURE 3.11
Predominant therapeutic approach in residential programmes, by overall number at national (left) and European (right) levels, 2011
 Therapeutic community/TC principles   Combined   Psychotherapy/cognitive behavioural therapy  
 Psychotherapy/other   12-step/Minnesota   No data
12-step/Minnesota 3 %
Psychotherapy/other 7 %
Psychotherapy/cognitive 
behavioural therapy 14 %
Combined 23 %
Therapeutic community/TC 
principles 50 %
No data 3 %
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employ groups that face disadvantages on the labour 
market. Although these interventions are available in most 
Member States (see Figure 3.13), access for people in 
drug treatment appears to be limited, and may be 
complicated by high unemployment rates in the general 
population. 
I Social reintegration: focusing on employability
Social reintegration services support treatment and 
prevent relapse by addressing key aspects of the social 
exclusion of drug users. In 2012, about half of the clients 
who entered specialised drug treatment in Europe were 
unemployed (47 %) and almost one in ten lacked stable 
accommodation (9 %). Low educational attainment was 
also common among this group. Although the social 
reintegration of drug users is mentioned as a key objective 
of national drug strategies, provision of these interventions 
varies considerably between countries.
Increasing the employability of drug treatment clients 
can help them to reintegrate into society. For individuals, 
employability depends on the knowledge, skills and 
attitudes they possess, the way they use those assets 
and the context within which they seek work. One way 
to achieve this is through a supportive system targeted 
at disadvantaged individuals, which aims to bridge the gap 
between long-term unemployment and the labour market. 
This system is often referred to as the intermediate labour 
market. Treatment clients may be offered temporary 
employment contracts, together with training, work 
experience, personal development and job search 
activities. Social enterprise projects are a type of initiative 
that is commonly considered under this heading. These 
enterprises produce socially useful goods or services and 
FIGURE 3.12
Availability of opioid substitution within residential  
programmes, 2011
 High availability   Low availability   Not available  
 No data
FIGURE 3.13
Availability of intermediate labour market interventions for drug 
treatment clients (expert ratings, 2011)
 Full/extensive   Limited/rare   Not applicable  
 No data
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Opioid substitution treatment is now provided in prisons 
in 26 of the 30 countries monitored by the EMCDDA, 
although its introduction was generally later than for 
community provision. Restrictions may also exist. For 
example, in four countries, substitution treatment in prison 
is limited to those already having a prescription prior to 
incarceration.
I  Evidence-informed responses: use of guidelines and standards
Europe’s health and social responses to drug problems 
are increasingly supported by guidelines and quality 
standards, which exist to translate evidence into 
satisfactory and sustainable results. In general, a process 
can be observed whereby guidelines precede by several 
years the introduction of quality standards (Figure 3.15).
I  Prison health largely remains with justice and interior ministries
Prisoners report higher overall rates of drug use than the 
general population and more harmful patterns of use, 
illustrated by recent studies showing that between 5 % and 
31 % of prisoners have ever injected drugs. On admission 
to prison, most users reduce or stop consuming drugs. 
Illicit drugs do, however, find their way into many prisons, 
and some prisoners continue or initiate use during 
incarceration.
Most countries have established interagency partnerships 
between prison health services and providers in the 
community. Such partnerships deliver health education 
and treatment interventions in prison and ensure 
continuity of care upon prison entry and release. Generally, 
prison health services remain the responsibility of 
ministries of justice or interior. In some countries, however, 
the ministry of health now has responsibility for the 
delivery of prison health service (Figure 3.14), facilitating 
greater integration with general health service provision in 
the community.
FIGURE 3.14
Ministerial responsibility for prison health service provision
 Ministry of Justice   Ministry of Interior   Ministry of Health  
 Ministry of Defence   No data available
FIGURE 3.15
Cumulative number of countries that have published guidelines and 
quality standards for health and social interventions in the drugs 
field, by year of publication
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Chapter 3 I Health and social responses to drug problems
Guidelines are statements that include recommendations 
intended to optimise client care. They are usually based 
on a systematic review of evidence and an assessment of 
the benefits and harms of alternative care options. 
The purpose of guidelines is to assist clients, carers and 
service providers in making decisions on the choice of 
appropriate interventions. During the last 20 years more 
than 150 sets of drug-related guidelines have been 
published, with guidelines available in all Member States 
since 2011. Guidelines span the full range of health and 
social interventions in the drugs field, although there are a 
larger number on health interventions such as substitution 
treatment and detoxification than on harm reduction and 
social reintegration (Figure 3.16). 
Quality standards are principles and sets of rules based on 
evidence, which are used to help implement the 
interventions recommended in guidelines. They can refer 
to content issues, processes or to structural aspects 
of quality assurance, such as the working environment 
and staffing composition. In the field of drug prevention, 
a European-level set of quality standards is available 
to support programme development. These standards 
highlight factors such as ensuring the relevance of 
activities to target populations, adherence to accepted 
ethical principles, and integration and promotion of the 
scientific evidence base.
FIGURE 3.16
National drug-related guidelines for health and social interventions 
in the drugs field reported in Europe up to 2013
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Harm reduction
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Chapter 4
Drug policies
At a European level, EU drugs legislation 
alongside multi-annual strategies and 
action plans provide a framework for 
coordinated action. At the national level, 
it is the responsibility of governments 
and parliaments to adopt the legal, 
strategic, organisational and budgetary 
frameworks necessary to respond to 
drug-related problems. 
Monitoring drug policies
Key policy dimensions that can be monitored at 
European level include: drug laws and drug law 
offences, national drug strategies and action plans, 
policy coordination and evaluation mechanisms, as 
well as drug-related budgets and public expenditure. 
Data are collected via two EMCDDA networks: the 
national focal points and the legal and policy 
correspondents. Data and methodological notes on 
drug law offences can be found in the European 
Drug Report: Data and statistics, and comprehensive 
information on European drug policy and law is also 
available online. 
I Drug laws: a common framework
The international framework for control of production, trade 
and possession of over 240 psychoactive substances is 
set out in three United Nations Conventions. These oblige 
each country to treat unauthorised supply as a criminal 
offence. The same is required for possession of drugs for 
personal use, but subject to a country’s ‘constitutional 
principles and the basic concepts of its legal system’. 
This clause has not been uniformly interpreted, and this is 
reflected in different legal approaches in European 
countries and elsewhere.
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I  Possession for use: moving away from prison sentences
The possession of drugs for personal use — and sometimes 
drug use — is a criminal offence in most European 
countries, where it can be punished by a custodial sentence. 
In many European countries, however, imprisonment is 
uncommon, and since around 2000, there has been an 
overall trend across Europe to reduce the possibility of 
imprisonment for offences related to personal use. Some 
countries have removed the possibility of incarceration 
entirely, and some countries have gone further so that 
personal possession offences can only be punished by 
non-criminal sanctions, usually a fine. 
FIGURE 4.1
Reported offences related to drug use or possession for use in Europe, trends and breakdown by drug
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FIGURE 4.2
Reported offences related to drug supply in Europe, trends and breakdown by drug
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In most European countries, the majority of reports of drug 
law offences relate to drug use or possession for use. In 
Europe, overall, it is estimated that more than one million 
of these offences were reported in 2012, a 17 % increase 
compared to 2006. More than three-quarters of the 
reported drug offences involve cannabis (Figure 4.1). 
I Drug supply: large variation in penalties
Illegal drug supply is always a crime across Europe, but the 
possible penalties vary considerably between countries. In 
some countries, supply offences may be subject to a single 
wide penalty range (up to life in prison). Other countries 
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I National drug strategies
It is now established practice for national governments in 
Europe to adopt drug strategies and action plans. These 
time-limited documents contain a set of general principles, 
objectives and priorities, specifying actions and the parties 
responsible for their implementation. Currently, all 
countries have a national drug strategy or action plan 
document, except Austria which has provincial plans. 
Seven countries have adopted national strategies and 
action plans that cover both licit and illicit drugs 
(Figure 4.3). Many countries now systematically evaluate 
their drug strategies and action plans. The aim of 
evaluation is generally to assess the level of 
implementation achieved, as well as the changes in the 
overall drug situation.
differentiate between minor and major supply offences, 
determined by factors such as the quantity or type of 
drugs found, with corresponding maximum and minimum 
penalties. 
Overall, reports of drug supply offences have increased by 
28 % since 2006, reaching more than 230 000 cases in 
2012. As with possession offences, cannabis accounted 
for the majority. Cocaine, heroin and amphetamines, 
however, accounted for a larger share of offences for 
supply than for personal possession. The downward trends 
in offences for cocaine and heroin supply have continued 
(Figure 4.2).
I  New psychoactive substances:  evolving control systems
The speed at which recently controlled substances have 
been replaced by new substances and the diversity of 
available products has severely challenged Europe’s 
lawmakers.
At national level, these challenges have prompted a variety 
of innovative legal responses among European countries. 
Broadly speaking, three types can be identified. First, 
countries may use existing laws that cover issues 
unrelated to controlled drugs, such as consumer safety 
legislation or medicines control legislation: in Poland, over 
1 000 retail outlets were closed over a weekend in 2010 
by using existing health protection powers. Secondly, 
countries may extend or adapt existing drug laws or 
processes: in the United Kingdom in 2011, Temporary 
Class Drug Orders were introduced to control supply while 
the risks to health are examined. Thirdly, countries may 
design new legislation: in 2013, Portugal and Slovakia 
introduced laws specifically to stop the unauthorised sale 
of certain new substances.
This fast-moving area of law continues to evolve. In recent 
developments, Poland and Romania strengthened existing 
laws by introducing specially designed new legislation; old 
and new are now used in parallel. In 2012, Cyprus 
redrafted their generic definitions to cover substances 
outside the current definitions, while in the same year the 
Netherlands rejected generic definitions on the basis that 
they were not sufficiently targeted. 
Among these different responses, there is wide variation in 
the criteria for triggering a legislative response and in the 
penalties for non-compliance. Nevertheless, there seems 
to be a trend towards countries focusing on penalising 
supply rather than possession of these substances.
 It is now established practice  
 for national governments in  
 Europe to adopt drug  
 strategies and action plans 
FIGURE 4.3
National drug strategies and action plans: availability and scope
 Combined licit and illicit drug strategy
 Illicit drug strategy   No national drug strategy
NB: While the United Kingdom has an illicit drug strategy, both Wales and
Northern Ireland have combined strategies which include alcohol.
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drug-related public expenditure in Europe represents a 
major obstacle and makes comparison between countries 
difficult. For the 16 countries that have produced 
estimates since 2002, drug-related public expenditure 
ranges from 0.01 % to 0.5 % of their gross domestic 
product (GDP). From the information available, it appears 
that the largest share of drug-related public expenditure is 
allocated to drug supply reduction activities (Figure 4.4).
Public expenditure on supply reduction includes, among 
other things, expenditure on drug-law offenders in prisons. 
The EMCDDA calculated a range of estimates, where the 
low estimate considers only those prisoners who have 
been sentenced for a drug-law offence and the high 
estimate also includes pre-trial prisoners who may be 
sentenced for a drug-law offence. Applying these criteria, 
European countries spent an estimated 0.03 % of GDP, 
or EUR 3.7 billion, on drug-law offenders in prison in 2010. 
Including pre-trial prisoners, the estimate rises to 0.05 % 
of GDP or EUR 5.9 billion.
I Diverse drug policy advocacy organisations 
Recent years have seen an increased involvement of civil 
society organisations, including drug policy advocacy 
groups, in the development of drug strategies. A recent 
EMCDDA study identified more than 200 organisations 
involved in drug policy advocacy in Europe, with around 
70 % of them active at national level and the remainder 
equally divided between local or European level advocacy. 
Almost two-thirds of these organisations had objectives 
focused on practice development, with 39 % advocating 
harm reduction approaches and 26 % advocating 
prevention and drug use reduction. The remaining 
organisations were focused on legislative change, with 
23 % favouring reduction of drug controls and 12 % 
advocating control reinforcement. 
Most advocacy organisations are engaged in targeted 
activities, aimed at influencing the attitudes and opinions 
of the public and policymakers on drug service provision 
and drug controls. They use awareness raising activities 
such as participating in public debates, or maintaining 
social media sites in order to influence drug policy. 
Organisations promoting control reduction or harm 
reduction mainly advocated on behalf of drug users, 
whereas organisations supporting drug use reduction and 
control reinforcement mainly advocated on behalf of the 
wider society and, in particular, young people and families. 
I  Economic evaluation: funds for interventions affected by austerity
Many European countries continue to face the 
consequences of the recent economic downturn. The 
extent of fiscal consolidation or austerity measures and 
their impact differs between European countries. Among 
the 18 countries with sufficient data to make a 
comparison, reductions were reported in health and public 
order and safety — the areas of government spending 
where most drug-related public expenditure originates. 
Overall, between 2009 and 2011, greater reductions in 
public expenditure were observed in the health sector. 
Cuts in funds available for drug-related programmes and 
services have also been reported by European countries, 
with drug prevention interventions and drug-related 
research particularly affected. Several countries also report 
that attempts to ring-fence the financing of drug treatment 
have not always succeeded. 
Economic analysis can be an important tool for policy 
evaluation, although the limited information available on 
FIGURE 4.4
Breakdown of drug-related public expenditure between demand 
reduction and supply reduction
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Annex: national data tables
OPIOIDS
Problem opioid 
use estimate
Treatment demand indicator, primary drug
Clients in 
substitution 
treatment
Opioid clients as %  
of treatment entrants
% opioid clients injecting  
(main route of administration)
All entrants First-time entrants All entrants
First-time 
entrants
Country cases per 1 000 % (count) % (count) % (count) % (count) count
Belgium – 34.5 (2 335) 17.1 (290) 21.7 (480) 12.4 (35) 17 351
Bulgaria – 82.5 (1 631) 84.3 (253) 78.5 (963) 80.3 (196) 3 445
Czech Republic 1.5–1.5 18.2 (1 615) 9.7 (417) 85.8 (1 370) 84.5 (348) 4 000
Denmark – 17.5 (663) 7.1 (102) 33.9 (193) 23 (20) 7 600
Germany 3.2–3.8 40.4 (30 841) 15.9 (3 343) – – 75 400
Estonia – 93.4 (510) 85.6 (107) 80.7 (406) 79.4 (85) 1 157
Ireland – 51.6 (3 971) 32.4 (1 058) 42.5 (1 633) 34.4 (353) 8 923
Greece 2.6–3.2 77.5 (4 399) 68.9 (1 652) 39.7 (1 744) 36.3 (600) 9 878
Spain 0.9–1.0 29.7 (14 925) 13.2 (3 289) 18.1 (2 537) 12.1 (384) 76 263
France – 43.1 (15 641) 27.1 (2 690) 14.2 (1 836) 6.8 (172) 152 000
Croatia 3.2–4.0 80.9 (6 357) 27.9 (313) 74.5 (4 678) 42.3 (126) 4 565
Italy 3.8–5.2 55.5 (16 751) 39 (5 451) 55.7 (8 507) 46.4 (2 185) 98 460
Cyprus 1.0–1.5 27.9 (278) 8.4 (41) 57.2 (159) 57.5 (23) 239
Latvia 5.4–10.7 49.9 (1 071) 26.3 (104) 91.3 (935) 80.9 (76) 355
Lithuania 2.3–2.4 – 66 (140) – 100 (140) 687
Luxembourg 5.0–7.6 58.8 (163) – 44.1 (71) – 1 226
Hungary 0.4–0.5 5.9 (230) 1.8 (47) 70.9 (156) 56.8 (25) 637
Malta 5.8–6.6 75.4 (1 410) 35.2 (93) 61 (840) 53.9 (48) 1 094
Netherlands 0.8–1.0 12.1 (1 302) 5.7 (352) 5.8 (45) 9 (19) 9 556
Austria 5.2–5.5 58 (2 110) 35.5 (488) 46.5 (727) 33.6 (127) 16 892
Poland 0.4–0.7 28.7 (808) 9 (104) 62.7 (449) 39.4 (39) 1 583
Portugal – 70.1 (2 637) 54.4 (980) 15.4 (147) 13.1 (80) 24 027
Romania – 37.4 (745) 25 (251) 89.3 (609) 86.5 (199) 531
Slovenia 4.0–4.8 81.1 (519) 64 (189) 50.6 (212) 39.7 (48) 3 345
Slovakia 1.0–2.5 26.3 (528) 13.1 (126) 74 (382) 69.6 (87) 465
Finland – 61.9 (920) 38.1 (101) 81 (728) 74 (74) 2 439
Sweden – 20.1 (248) – 60.9 (148) – 5 200
United Kingdom 7.9–8.3 56.4 (61 737) 33.4 (13 586) 34.5 (20 804) 30.6 (4 085) 171 082
Turkey 0.2–0.5 75.4 (3 557) 67.3 (1 695) 48.7 (1 734) 43.1 (730) 28 656
Norway 2.1–3.9 32.6 (2 902) – 77.1 (145) – 7 038
European Union – 45.5 (174 345) 25.0 (35 567) 38.2 (50 759) 31.8 (9 574) 698 441
EU, Turkey and 
Norway
– 45.5 (181 804) 25.7 (37 262) 38.5 (52 638) 32.4 (10 304) 734 135
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COCAINE
Prevalence estimates Treatment demand indicator, primary drug
General population School population
Cocaine clients as % of 
treatment entrants
% cocaine clients injecting 
(main route of administration)
Lifetime, 
adult 
(15–64)
Last 12 
months, 
young adult 
(15–34)
Lifetime, 
students 
(15–16)
All entrants First-time entrants All entrants
First-time 
entrants
Country % % % % (count) % (count) % (count) % (count)
Belgium – 2.0 4 15.3 (1 031) 16.3 (277) 7.4 (72) 2.2 (6) 
Bulgaria 0.9 0.3 3 0.5 (9) 1 (3) 0 (0) 0 (0) 
Czech Republic 2.3 0.5 1 0.2 (19) 0.2 (10) 0 (0) 0 (0) 
Denmark 5.2 2.4 2 5.1 (193) 5.8 (84) 10.1 (17) 0 (0) 
Germany 3.4 1.6 3 6.1 (4 620) 6 (1 267) – –
Estonia – 1.3 2 – – – –
Ireland 6.8 2.8 3 8.5 (654) 9.1 (297) 1.5 (9) 0 (0) 
Greece 0.7 0.2 1 4.1 (235) 4.2 (101) 19.4 (45) 8.9 (9) 
Spain 8.8 3.6 3 40.4 (20 335) 42.5 (10 637) 1.9 (371) 0.9 (97) 
France 3.7 1.9 4 6.4 (2 311) 4.1 (411) 9.9 (192) 4.1 (16) 
Croatia 2.3 0.9 2 1.9 (147) 4.3 (48) 3.5 (5) 2.2 (1) 
Italy 4.2 1.3 1 24.2 (7 299) 30 (4 187) 4.1 (282) 3.4 (134) 
Cyprus 1.3 0.6 4 12.1 (121) 6.2 (30) 2.5 (3) 0 (0) 
Latvia 1.5 0.3 – 0.3 (6) 0.5 (2) 0 (0) 0 (0) 
Lithuania 0.9 0.3 2 – – – –
Luxembourg – – – 12.6 (35) – 39.4 (13) –
Hungary 0.9 0.4 2 1.6 (62) 1.6 (41) 11.5 (7) 7.5 (3) 
Malta 0.4 – 4 13.4 (251) 28 (74) 30.7 (75) 14.5 (10) 
Netherlands 5.2 2.4 2 26.5 (2 867) 21.7 (1 328) 0.1 (2) 0.1 (1) 
Austria 2.2 1.2 – 8.3 (301) 10.2 (140) 6.5 (19) 1.5 (2) 
Poland 0.9 0.3 3 2.4 (69) 2.7 (31) 6.1 (4) 3.2 (1) 
Portugal 1.2 0.4 4 10.5 (397) 14.4 (259) 3.6 (8) 1 (2) 
Romania 0.3 0.2 2 1.2 (23) 1.9 (19) 0 (0) 0 (0) 
Slovenia 2.1 1.2 3 4.8 (25) 4.2 (8) 40 (10) 12.5 (1) 
Slovakia 0.6 0.4 2 0.5 (11) 0.9 (9) 0 (0) 0 (0) 
Finland 1.7 0.6 1 – – – –
Sweden 3.3 1.2 1 1.8 (16) – 0 (0) –
United Kingdom 9.0 3.3 4 12.6 (13 787) 16.9 (6 887) 2.1 (279) 0.9 (58) 
Turkey – – – 1.7 (82) 2 (50) 0 (0) 0 (0) 
Norway – – 1 0.8 (67) – 0 (0) –
European Union 4.2 1.7 – 14.3 (54 824) 18.4 (26 150) 3 (1 413) 1.5 (341)
EU, Turkey and 
Norway
– – – 13.9 (54 973) 18.1 (26 200) 3 (1 413) 1.5 (341)
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AMPHETAMINES
Prevalence estimates Treatment demand indicator, primary drug
General population School population
Amphetamines clients as % of 
treatment entrants
% amphetamines clients 
injecting (main route of 
administration)
Lifetime, 
adult 
(15–64)
Last 12 
months, 
young adult 
(15–34)
Lifetime, 
students 
(15–16)
All entrants First-time entrants All entrants
First-time 
entrants
Country % % % % (count) % (count) % (count) % (count)
Belgium – – 5 9.4 (639) 7.4 (125) 15.4 (86) 9.8 (12) 
Bulgaria 1.2 1.3 6 2.2 (43) 8 (24) 0 (0) 0 (0) 
Czech Republic 2.5 0.8 2 67.4 (5 999) 71 (3 040) 80.1 (4 761) 75.2 (2 255) 
Denmark 6.6 1.4 2 9.5 (358) 10.3 (149) 3.1 (9) 0 (0) 
Germany 3.1 1.8 4 13.1 (9 959) 16.7 (3 498) – –
Estonia – 2.5 3 2.4 (13) 2.4 (3) 75 (9) 66.7 (2) 
Ireland 4.5 0.8 2 0.6 (45) 0.8 (25) 0 (0) 0 (0) 
Greece 0.1 0.1 2 0.1 (7) 0.1 (2) 0 (0) 0 (0) 
Spain 3.3 1.1 2 1.2 (595) 1.5 (363) 0.3 (2) 0 (0) 
France 1.7 0.5 4 0.3 (98) 0.2 (22) 22.5 (18) 15.8 (3) 
Croatia 2.6 1.6 2 1.1 (85) 2 (22) 1.2 (1) 0 (0) 
Italy 1.8 0.1 1 0.1 (33) 0.2 (22) 0 (0) 0 (0) 
Cyprus 0.7 0.4 4 – – – –
Latvia 2.2 0.6 – 19.8 (426) 27.1 (107) 60.4 (223) 56.3 (54) 
Lithuania 1.2 0.5 3 – 5.7 (12) – 75 (9) 
Luxembourg – – – 0.7 (2) – 0 (0) –
Hungary 1.8 1.2 6 12.3 (476) 11.1 (285) 20 (94) 16 (45) 
Malta 0.4 – 3 0.3 (5) 0.4 (1) 20 (1) 0 (0) 
Netherlands 3.1 – 3 5.9 (633) 6.1 (372) 1.8 (6) 0.5 (1) 
Austria 2.5 0.9 – 3.2 (117) 4.3 (59) 0 (0) 0 (0) 
Poland 2.9 1.4 4 21.7 (611) 22.4 (260) 10.1 (60) 3.5 (9) 
Portugal 0.5 0.1 3 0.03 (1) 0.1 (1) – –
Romania 0.1 0.0 2 0.5 (9) 0.4 (4) 0 (0) 0 (0) 
Slovenia 0.9 0.8 2 1 (5) 2.1 (4) 0 (0) 0 (0) 
Slovakia 0.5 0.3 2 44.7 (895) 49.3 (474) 27.8 (244) 19.2 (90) 
Finland 2.3 1.6 1 12.2 (181) 9.8 (26) 80.4 (135) 68 (17) 
Sweden 5.0 1.5 1 14.9 (130) – 76.5 (176) –
United Kingdom 10.6 1.1 2 2.8 (3 084) 3.3 (1 329) 26.1 (744) 19.4 (241) 
Turkey 0.3 – – – – – –
Norway – – 1 11.9 (1 057) – 70.2 (203) –
European Union 3.4 0.9 – 6.5 (24 553) 7.2 (10 229) 48 (6 569) 43 (2 738)
EU, Turkey and 
Norway
– – – 6.5 (25 610) 7.1 (10 229) 48.5 (6 772) 43 (2 738)
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ECSTASY
Prevalence estimates Treatment demand indicator, primary drug
General population School population Ecstasy clients as % of treatment entrants
Lifetime,  
adult (15–64)
Last 12 months, 
young adult 
(15–34)
Lifetime, students 
(15–16) All entrants
First-time  
entrants
Country % % % % (count) % (count)
Belgium – – 4 0.5 (36) 1.1 (19)
Bulgaria 2.0 2.9 4 – –
Czech Republic 3.6 1.2 3 0.1 (6) 0.1 (3)
Denmark 2.3 0.7 1 0.3 (13) 0.5 (7)
Germany 2.7 0.9 2 – –
Estonia – 2.3 3 – –
Ireland 6.9 0.9 2 0.6 (46) 1 (32)
Greece 0.4 0.4 2 0.2 (10) 0.2 (4)
Spain 3.6 1.4 2 0.2 (103) 0.3 (78)
France 2.4 0.4 3 0.5 (186) 0.2 (22)
Croatia 2.5 0.5 2 0.4 (31) 0.4 (4)
Italy 1.8 0.1 1 0.2 (61) 0.2 (32)
Cyprus 0.9 0.3 3 0.2 (2) 0.2 (1)
Latvia 2.7 0.8 3 0.2 (4) 0.5 (2)
Lithuania 1.3 0.3 2 – –
Luxembourg – – – – –
Hungary 2.4 1.0 4 1.5 (57) 1.3 (34)
Malta 0.7 – 3 1.1 (20) 2.7 (7)
Netherlands 6.2 3.1 3 0.6 (66) 0.9 (58)
Austria 2.3 1.0 – 0.7 (24) 0.9 (13)
Poland 1.1 0.3 2 0.2 (7) 0.2 (2)
Portugal 1.3 0.6 3 0.1 (4) 0.2 (4)
Romania 0.7 0.4 2 0.2 (3) 0.2 (2)
Slovenia 2.1 0.8 2 0.4 (2) 1.1 (2)
Slovakia 1.9 0.9 4 – –
Finland 1.8 1.1 1 0.1 (2) 0.4 (1)
Sweden 2.1 0.2 1 – –
United Kingdom 8.3 2.4 4 0.2 (270) 0.4 (166)
Turkey 0.1 0.1 – 1.1 (53) 1.6 (41)
Norway – – 1 – –
European Union 3.1 1.0 – 0.2 (953) 0.3 (493)
EU, Turkey and 
Norway
– – – 0.3 (1 006) 0.4 (534)
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CANNABIS
Prevalence estimates Treatment demand indicator, primary drug
General population School population Cannabis clients as % of treatment entrants
Lifetime, adult 
(15–64)
Last 12 months, 
young adult 
(15–34)
Lifetime, students 
(15–16) All entrants
First-time  
entrants
Country % % % % (count) % (count)
Belgium 14.3 11.2 24 31.2 (2 112) 49.4 (839)
Bulgaria 7.5 8.3 21 3.4 (67) 5.7 (17)
Czech Republic 27.9 18.5 42 12.5 (1 111) 17.5 (747)
Denmark 35.6 17.6 18 63.4 (2 397) 72.6 (1 048)
Germany 23.1 11.1 19 34.4 (26 208) 54.5 (11 431)
Estonia – 13.6 24 2.9 (16) 8 (10)
Ireland 25.3 10.3 18 28.8 (2 216) 45.8 (1 498)
Greece 8.9 3.2 8 15.7 (889) 24.6 (589)
Spain 27.4 17.0 28 25.6 (12 873) 38.9 (9 736)
France 32.1 17.5 39 44.1 (16 020) 62.5 (6 206)
Croatia 15.6 10.5 18 12.7 (1 001) 56.3 (630)
Italy 21.7 8.0 14 17.1 (5 176) 26 (3 629)
Cyprus 9.9 4.2 7 53.3 (532) 81.9 (399)
Latvia 12.5 7.3 25 14.6 (314) 26.8 (106)
Lithuania 10.5 5.1 20 – 3.3 (7)
Luxembourg – – – 26 (72) –
Hungary 8.5 5.7 19 65.9 (2 560) 74.9 (1 927)
Malta 3.5 1.9 10 8.4 (157) 29.2 (77)
Netherlands 25.7 13.7 26 47.6 (5 143) 57.8 (3 542)
Austria 14.2 6.6 – 25.3 (919) 45.4 (623)
Poland 12.2 12.1 23 35.6 (1 003) 53.6 (623)
Portugal 9.4 5.1 14 13.9 (525) 25.4 (457)
Romania 1.6 0.6 7 11.1 (222) 18.1 (182)
Slovenia 15.8 10.3 23 10.4 (54) 26.5 (50)
Slovakia 10.5 7.3 27 21.6 (432) 32 (308)
Finland 18.3 11.2 11 18 (267) 42.6 (113)
Sweden 14.9 6.9 7 16 (197) –
United Kingdom 30.0 10.5 24 22.4 (24 498) 37.1 (15 107)
Turkey 0.7 0.4 – 15.8 (744) 22 (555)
Norway 19.2 7.9 5 19.2 (1 711) –
European Union 21.7 11.2 – 27.9 (106 981) 42.2 (59 901)
EU, Turkey and 
Norway
– – – 27.6 (109 436) 41.8 (60 456)
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OTHER INDICATORS
Drug-induced deaths 
(aged 15–64)
HIV diagnoses among 
injecting drug users 
(ECDC)
Injecting drug use 
estimate
Syringes distributed 
through specialised 
programmes
Country cases per million population (count)
cases per million 
population (count)
cases per  
1 000 population count
Belgium 17.4 (127) 0.4 (4) 2.5–4.8 937 924
Bulgaria 4.8 (24) 5.5 (40) – 466 603
Czech Republic 3.9 (28) 0.6 (6) 5.32–5.38 5 362 334
Denmark 46.3 (168) 2 (11) – –
Germany 16.8 (908) 1 (81) – –
Estonia 190.8 (170) 53.7 (72) 4.3–10.8 2 228 082
Ireland 70.5 (215) 2.8 (13) – 274 475
Greece – 42.9 (484) 0.93–1.25 406 898
Spain 11.4 (360) 4.4 (166) 0.19–0.21 1 990 136
France 6.7 (283) 1.2 (76) – 13 800 000
Croatia 16.1 (46) 0.2 (1) 0.3–0.6 256 544
Italy 10.1 (390) 3.4 (208) – –
Cyprus 12 (7) 0 (0) 0.2–0.4 0
Latvia 12.4 (17) 46 (94) – 311 188
Lithuania 34.7 (70) 20.6 (62) – 196 446
Luxembourg 22.1 (8) 7.6 (4) 4.5–6.85 212 822
Hungary 3.5 (24) 0 (0) 0.8 420 812
Malta 16.2 (4) 0 (0) – 376 104
Netherlands 10.2 (113) 0.4 (7) 0.21–0.22 237 400
Austria 28.1 (160) 4.5 (38) – 4 625 121
Poland 9.9 (271) 1.1 (42) – 98 000
Portugal 4.2 (29) 5.3 (56) – 1 341 710
Romania 2 (28) 8 (170) – 1 074 394
Slovenia 18.4 (26) 0.5 (1) – 553 426
Slovakia 6.2 (24) 0.2 (1) – 11 691
Finland 58 (205) 1.3 (7) – 3 539 009
Sweden 62.6 (383) 1.7 (16) – 73 125
United Kingdom 38.3 (1 598) 1.8 (111) 2.9–3.2 9 349 940
Turkey 3.1 (154) 0.1 (6) – –
Norway 75.9 (250) 2.2 (11) 2.2–3.1 3 011 000
European Union 17.1 (5 686) 3.5 (1 771) – –
EU, Turkey and 
Norway
– 3.1 (1 788) – –
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SEIZURES
Heroin Cocaine Amphetamines Ecstasy
Quantity 
seized
Number of 
seizures
Quantity 
seized
Number of 
seizures
Quantity 
seized
Number of 
seizures Quantity seized
Number of 
seizures
Country kg count kg count kg count tablets (kg) count
Belgium 112 1 953 19 178 3 349 58 2 641 26 874 (–) 1 015
Bulgaria 285 44 115 30 84 68 6 164 (30) 3
Czech Republic 8 41 8 44 32 357 1 782 (0.01) 12
Denmark 41 430 42 2 056 303 1 817 72 654 (–) 523
Germany 242 3 381 1 258 3 618 1 196 11 919 313 179 (–) 1 786
Estonia 0.0004 1 3 49 41 319 9 210 (0.01) 56
Ireland 60 766 459 391 23 143 148 195 (6) 311
Greece 331 2 045 201 432 0.3 22 3 253 (0.4) 7
Spain 229 5 822 20 754 37 880 251 2 511 175 381 (–) 2 128
France 701 – 5 602 – 307 – 156 337 (–) –
Croatia 30 192 6 132 3 268 – (1.1) 105
Italy 951 2 983 5 319 6 633 12 63 19 051 (20) 138
Cyprus 1 34 7 88 0.5 50 102 (0.1) 9
Latvia 1 427 1 28 30 820 847 (–) 24
Lithuania 0.5 112 120 10 80 119 54 (–) 8
Luxembourg 3 190 2 122 1 13 137 (–) 10
Hungary 3 26 13 118 30 492 12 437 (0.8) 91
Malta 1 44 143 80 0.2 3 1 080 (–) 27
Netherlands 750 – 10 000 – 681 – 2 442 200 (61) –
Austria 222 393 65 912 35 607 8 998 (–) 113
Poland 36 – 213 – 618 – 31 092 (0.01) –
Portugal 66 971 4 020 1 238 0.2 44 867 (7) 101
Romania 45 215 55 85 4 16 12 861 (0.02) 112
Slovenia 20 439 27 251 9 203 960 (–) 16
Slovakia 0.3 82 2 19 11 607 529 (–) 16
Finland 0.07 47 26 147 139 2 616 23 623 (–) 513
Sweden 7 363 34 1 010 361 3 609 38 630 (3) 441
United Kingdom 831 10 624 3 324 18 569 1 491 6515 473 000 (–) 3 716
Turkey 13 301 4 155 476 1 434 619 108 2 961 553 (357) 4 445
Norway 45 1 277 67 860 317 6 801 6 579 (2) 274
European Union 4 977 31 625 70 997 77 291 5 802 35 842 3 979 497 (130) 11 281
EU, Turkey and 
Norway
18 323 37 057 71 540 79 585 6 737 42 751 6 947 629 (489) 16 000
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SEIZURES (continued)
Cannabis resin Herbal cannabis Cannabis plants
Quantity seized Number of seizures Quantity seized
Number of 
seizures Quantity seized
Number of 
seizures
Country kg count kg count plants (kg) count
Belgium 1 338 4 500 5 635 19 672 330 675 1 111
Bulgaria 15 967 4 1 319 127 13 072 (2 517) 26
Czech Republic 21 24 563 558 90 091 (–) 259
Denmark 1 334 9 239 223 1 287 – (1 401) 675
Germany 2 386 6 490 4 942 28 744 97 829 (–) 2 204
Estonia 5 48 25 466 – (7) 12
Ireland 1 185 527 1 020 1 843 11 601 (–) 542
Greece 44 145 22 383 6 262 34 040 (–) 831
Spain 325 563 179 993 10 457 150 206 – (39 932) 1 677
France 51 118 – 3 270 – 131 307 (–) –
Croatia 23 343 1 070 4 098 6 703 (–) 211
Italy 21 893 6 184 21 496 4 660 4 122 617 (–) 1 216
Cyprus 0.1 20 100 863 385 (–) 39
Latvia 117 64 74 414 – (335) 4
Lithuania 424 23 96 242 – (–) –
Luxembourg 1 83 30 774 39 (–) 9
Hungary 3 103 1 777 2 092 7 382 (–) 193
Malta 16 96 3 50 46 (–) 5
Netherlands 2 200 – 12 600 – 1 400 000 (–) –
Austria 174 1 192 812 5 732 – (173) 210
Poland 39 – 1 489 – 61 585 (–) –
Portugal 18 304 3 298 49 554 7 788 (–) 397
Romania 27 1 492 335 262 3 125 (300) 30
Slovenia 3 66 706 3 350 11 166 (–) 174
Slovakia 1 17 177 1 242 2 927 (–) 38
Finland 714 1 870 – 5 036 18 150 (66) 3 339
Sweden 1 091 6 761 641 7 611 – –
United Kingdom 13 432 17 360 13 243 148 746 555 625 15 846
Turkey 27 413 6 881 124 673 57 744 – 3 646
Norway 1 605 10 985 314 4 402 – (133) 364
European Union 457 424 239 942 104 535 394 891 6 906 153 (44 730) 29 048
EU, Turkey and 
Norway
486 442 257 808 229 522 457 037 6 906 153 (44 863) 33 058
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About this report
The Trends and developments report presents  
a top-level overview of the drug phenomenon in Europe, 
covering drug supply, use and public health problems 
as well as drug policy and responses. Together with the 
online Data and statistics, Country overviews and 
Perspectives on drugs, it makes up the 2014 European 
Drug Report package. 
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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